

EXPRESS MAIL NUMBER
EL852296784 US

5

**SEQUENCE SPECIFIC RECOMBINASE-BASED METHODS FOR
PRODUCING INTRON CONTAINING VECTORS AND COMPOSITIONS FOR
USE IN PRACTICING THE SAME**

10

CROSS-REFERENCE TO RELATED APPLICATIONS

Pursuant to 35 U.S.C. §119(e), this application claims priority to the filing date of United States Provisional Patent Application Serial No. 60/263,358 filed January 18, 2001; the disclosure of which applications is herein incorporated by reference.

15

INTRODUCTION

Field of the Invention

20

The field of this invention is molecular biology, particularly recombinant DNA engineering.

Background of the Invention

25

The processes of isolating, cloning and expressing genes are central to the field of molecular biology and play prominent roles in research and industry in biotechnology and related fields. Until recently, the isolation and cloning of genes has been achieved *in vitro* using restriction endonucleases and DNA ligases.

30

Restriction endonucleases are enzymes which recognize and cleave double-stranded DNA at a specific nucleotide sequence, and DNA ligases are enzymes which join fragments of DNA together via the phosphodiester bond. A DNA sequence of interest can be "cut" or digested into manageable pieces using a restriction endonuclease and then inserted into an appropriate vector for cloning using DNA ligase. However, in order to transfer the DNA of interest into a

B, F & F Ref: CLON-069

Clontech Ref: P-90

F:\DOCUMENT\CLON\069\patent application.doc

different vector--most often a specialized expression vector--restriction enzymes must be used again to excise the DNA of interest from the cloning vector, and then DNA ligase is used again to ligate the DNA of interest into the chosen expression vector.

5 The ability to transfer a DNA of interest to an appropriate expression vector is often limited by the availability or suitability of restriction enzyme recognition sites. Often multiple restriction enzymes must be employed to remove the desired coding region. Further, the reaction conditions used for each enzyme may differ such that it is necessary to perform the excision reaction in separate
10 steps, or it may be necessary to remove a particular enzyme used in an initial restriction enzyme reaction prior to completing subsequent restriction enzyme digestions due to buffer and/or cofactor incompatibility. Many of these extra steps require time-consuming purification of the subcloning intermediate.

 There is, therefore, a need to develop protocols and compositions for the
15 rapid transfer of a DNA molecule of interest from one vector to another *in vitro* or *in vivo* without the need to rely upon restriction enzyme digestions. To address this need, a number of different sequence specific recombinase based methods have been developed which allow one to transfer sequence material among vectors without restriction enzyme digestions. These systems include the
20 commercially available Creator and Gateway sequence specific recombinase based methods, where representative systems are described in U.S. Patent Nos. 5,581,808 and 5,888,732; as well as in Published PCT Application Serial Nos. WO 00/12687 and WO 01/05961.

 While the above protocols and systems are effective, there is room for
25 improvement. For example, in the above systems, expression vectors that are produced by the methods encode fusion proteins of the gene of interest fused to a sequence encoded by the sequence specific recombinase site of the vector. In many instances, such a fusion sequence is undesirable.

 As such, there is continued interest in the improvement of these sequence
30 specific recombinase systems. Of particular interest would be the development of such a system that produced expression vectors where the protein of interest was

not expressed a fusion with sequence specific recombinase encoded sequences.
The present invention satisfies this interest.

Relevant Literature

References of interest include: U.S. Patent Nos. 5,527,695; 5,744,336; 5,851,808; 5,888,732; and 5,962,255; as well as in Published PCT Application Serial Nos. WO 00/12687 and WO 01/05961. Also of interest is: Kaartinen & Nagy, Genesis (2001) 31: 126-129; and Yoshimura et al., Mol. Urol. (2001) 5: 81-4.

SUMMARY OF THE INVENTION

Methods are provided for producing a vector that includes at least one splicable intron. In the subject methods, intron containing vectors are produced from donor and acceptor vectors that each include a sequence specific recombinase site, where the subject donor and acceptor vectors further include splice donor and acceptor sites that, upon sequence specific recombination of the donor and acceptor vectors, define an intron in the product vector of the recombination step. Also provided are compositions for use in practicing the subject methods, including the donor and acceptor vectors themselves, as well as systems and kits that include the same. The subject invention finds use in a variety of different applications, including the production of expression vectors that encode C-terminal tagged fusion proteins, the production of expression vectors that encode pure protein and not a fusion thereof with N- and/or C-terminal sequence specific recombinase site encoded residues, and the like.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 provides a map of the pDNR-Dual donor vector described in greater detail below.

Figure 2 provides a map of the pLPS-EGFP acceptor vector described in greater detail below.

Figure 3 provides a map of the pDNR-Dual-Luc vector described in greater detail below.

Figure 4 provides a map of the pLPS-Luc-EGFP vector described in greater detail below.

Figure 5 provides a flow diagram of a representative method according to the subject invention.

DEFINITIONS

The terms "sequence-specific recombinase" and "site-specific recombinase" refer to enzymes or recombinases that recognize and bind to a short nucleic acid site or "sequence-specific recombinase target site", i.e., a recombinase recognition site, and catalyze the recombination of nucleic acid in relation to these sites. These enzymes include recombinases, transposases and integrases.

The terms "sequence-specific recombinase target site", "site-specific recombinase target site", "sequence-specific target site" and "site-specific target site" refer to short nucleic acid sites or sequences, i.e., recombinase recognition sites, which are recognized by a sequence- or site-specific recombinase and which become the crossover regions during a site-specific recombination event. Examples of sequence-specific recombinase target sites include, but are not limited to, lox sites, att sites, dif sites and frt sites.

The term "lox site" as used herein refers to a nucleotide sequence at which the product of the cre gene of bacteriophage P1, the Cre recombinase, can catalyze a site-specific recombination event. A variety of lox sites are known in the art, including the naturally occurring loxP, loxB, loxL and loxR, as well as a number of mutant, or variant, lox sites, such as loxP511, loxP514, lox Δ 86, lox Δ 117, loxC2, loxP2, loxP3 and lox P23.

The term "frt site" as used herein refers to a nucleotide sequence at which the product of the FLP gene of the yeast 2 micron plasmid, FLP recombinase, can catalyze site-specific recombination.

The term "unique restriction enzyme site" indicates that the recognition sequence of a given restriction enzyme appears once within a nucleic acid molecule.

A restriction enzyme site or restriction site is said to be located "adjacent to the 3' end of a sequence-specific recombinase target site" if the restriction enzyme recognition site is located downstream of the 3' end of the sequence-specific recombinase target site. The adjacent restriction enzyme site may, but need not, be contiguous with the last or 3' most nucleotide comprising the sequence-specific recombinase target site.

The term "intron" as used herein refers to a domain of a vector produced by the subject methods that is flanked on the 5' end by a splice donor site and on the 3' end by a splice acceptor site, where under appropriate conditions the intron is spliced out of or removed from an mRNA sequence expressed from the vector in which it is present.

The term "splice donor site" as used herein refers to a sequence or domain of a nucleic acid present at the 5' end of an intron, as defined above, that marks the start of the intron and its boundary with the preceding coding sequence – exon.

The term "splice acceptor site" as used herein refers to a sequence or domain of a nucleic acid present at the 3' end of an intron, as defined above, that marks the start of the intron and its boundary with the following coding sequence –exon.. In the present invention, the splice acceptor site is also meant to include the intron Branch point, which is required together with the splice donor and splice acceptor sequence in order for splicing to occur. The branch point marks the point to which the 5'end of the intron becomes joined during the process of splicing. For convenience, in the present embodiments, the splice Acceptor sequence and the Branch site are placed adjacent to each other so that they can be encoded within a single synthetic oligonucleotide for ease of vector construction. Thus, they are described here as a single unit. However, they may be further separated, by moving the branch site further 5' of the splice acceptor

sequence, provided that it is not moved 5' of the splice donor sequence and provided that splicing efficiency is not hindered.

The Term "splice site" as used herein refers to a sequence or domain of a nucleic acid present at either the 5' end or the 3' end of an intron as defined above.

The terms "polylinker" or "multiple cloning site" refer to a cluster of restriction enzyme sites, typically unique sites, on a nucleic acid construct that can be utilized for the insertion and/or excision of nucleic acid sequences, such as the coding region of a gene, loxP sites, etc.

The term "termination sequence" refers to a nucleic acid sequence which is recognized by the polymerase of a host cell and results in the termination of transcription. Prokaryotic termination sequences commonly comprise a GC-rich region that has a two-fold symmetry followed by an AT-rich sequence. A commonly used termination sequence is the T7 termination sequence. A variety of termination sequences are known in the art and may be employed in the nucleic acid constructs of the present invention, including the TINT3, TL13, TL2, TR1, TR2, and T6S termination signals derived from the bacteriophage lambda, and termination signals derived from bacterial genes, such as the trp gene of *E. coli*.

The terms "polyadenylation sequence" (also referred to as a "poly A⁺ site" or "poly A⁺ sequence") as used herein denotes a DNA sequence which directs both the termination and polyadenylation of the nascent RNA transcript. Efficient polyadenylation of the recombinant transcript is desirable, as transcripts lacking a poly A⁺ tail are typically unstable and rapidly degraded. The poly A⁺ signal utilized in an expression vector may be "heterologous" or "endogenous". An endogenous poly A⁺ signal is one that is found naturally at the 3' end of the coding region of a given gene in the genome. A heterologous poly A⁺ signal is one which is isolated from one gene and placed 3' of another gene, e.g., coding sequence for a protein. A commonly used heterologous poly A⁺ signal is the SV40 poly A⁺ signal. The SV40 poly A⁺ signal is contained on a 237 bp *Bam*HI/*Bcl*II restriction fragment and directs both termination and polyadenylation;

numerous vectors contain the SV40 poly A⁺ signal. Another commonly used heterologous poly A⁺ signal is derived from the bovine growth hormone (BGH) gene; the BGH poly A⁺ signal is also available on a number of commercially available vectors. The poly A⁺ signal from the Herpes simplex virus thymidine kinase (HSV tk) gene is also used as a poly A⁺ signal on a number of commercial expression vectors.

As used herein, the terms "selectable marker" or "selectable marker gene" refer to a gene which encodes an enzymatic activity and confers the ability to grow in medium lacking what would otherwise be an essential nutrient; in addition, a selectable marker may confer upon the cell in which the selectable marker is expressed, resistance to an antibiotic or drug. A selectable marker may be used to confer a particular phenotype upon a host cell. When a host cell must express a selectable marker to grow in selective medium, the marker is said to be a positive selectable marker (e.g., antibiotic resistance genes which confer the ability to grow in the presence of the appropriate antibiotic). Selectable markers can also be used to select against host cells containing a particular gene; selectable markers used in this manner are referred to as negative selectable markers.

As used herein, the term "construct" is used in reference to nucleic acid molecules that transfer DNA segment(s) from one cell to another. The term "vector" is sometimes used interchangeably with "construct". The term "construct" includes circular nucleic acid constructs such as plasmid constructs, phagemid constructs, cosmid vectors, etc., as well as linear nucleic acid constructs including, but not limited to, PCR products. The nucleic acid construct may comprise expression signals such as a promoter and/or an enhancer in operable linkage, and then is generally referred to as an "expression vector" or "expression construct".

The term "expression construct" as used herein refers to an expression module or expression cassette made up of a recombinant DNA molecule containing a desired coding sequence and appropriate nucleic acid sequences necessary for the expression of the operably linked coding sequence in a

particular host organism. Nucleic acid sequences necessary for expression in prokaryotes usually include a promoter and a ribosome binding site, often along with other sequences. Eukaryotic cells are known to utilize promoters, enhancers, and termination and polyadenylation signals.

5 The terms "in operable combination", "in operable order" and "operably linked" as used herein refer to the linkage of nucleic acid sequences in such a manner that a nucleic acid molecule capable of directing the transcription of a given gene and/or the synthesis of a desired protein molecule is produced. The terms also refer to the linkage of amino acid sequences in such a manner so that
10 the reading frame is maintained and a functional protein is produced.

 A cell has been "transformed" or "transfected" with exogenous or heterologous DNA when such DNA has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the
15 transforming DNA may be maintained on an episomal element such as a vector or plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells
20 containing the transforming DNA. A "clone" is a population of cells derived from a single cell or ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth *in vitro* for many generations. An organism, such as a plant or animal, that has been transformed with exogenous DNA is termed "transgenic".

25 Transformation of prokaryotic cells may be accomplished by a variety of means known in the art, including the treatment of host cells with CaCl_2 to make competent cells, electroporation, etc. Transfection of eukaryotic cells may be accomplished by a variety of means known in the art, including calcium phosphate-DNA co-precipitation, DEAE-dextran-mediated transfection,
30 polybrene-mediated transfection, electroporation, microinjection, liposome fusion, lipofection, protoplast fusion, retroviral infection, and biolistics.

As used herein, the term "host" is meant to include not only prokaryotes, but also eukaryotes, such as yeast, plant and animal cells. A recombinant DNA molecule or gene can be used to transform a host using any of the techniques commonly known to those of ordinary skill in the art. Prokaryotic hosts may include *E. coli*, *S. typhimurium*, *Serratia marcescens* and *Bacillus subtilis*. Eukaryotic hosts include yeasts such as *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Pichia pastoris*, mammalian cells and insect cells, and, plant cells, such as *Arabidopsis thaliana* and *Tobaccum nicotiana*.

As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence.

"Recombinant DNA technology" refers to techniques for uniting two heterologous DNA molecules, usually as a result of *in vitro* ligation of DNAs from different organisms. Recombinant DNA molecules are commonly produced by experiments in genetic engineering. Synonymous terms include "gene splicing", "molecular cloning" and "genetic engineering". The product of these manipulations results in a "recombinant" or "recombinant molecule". The term "recombinant protein" or "recombinant polypeptide" as used herein refers to a protein molecule that is expressed from a recombinant DNA molecule.

The ribose sugar is a polar molecule, and therefore, DNA is referred to as having a 5' to 3', or 5' to 3', directionality. DNA is said to have "5' ends" and "3' ends" because mononucleotides are reacted to make oligonucleotides in a manner such that the 5' phosphate of one mononucleotide pentose ring is attached to the 3' oxygen of its neighbor via a phosphodiester linkage. Therefore, an end of an oligonucleotide is referred to as the "5' end" if its 5' phosphate is not linked to the 3' oxygen of a mononucleotide pentose ring and as the "3' end" if its 3' oxygen is not linked to a 5' phosphate of a subsequent mononucleotide pentose ring. As used herein, a nucleic acid sequence, even if internal to a larger oligonucleotide, also has a 5' to 3' orientation. In either a linear or circular DNA molecule, discrete elements are referred to as being "upstream" or "5'" of the "downstream" or "3'" elements. This terminology reflects the fact that DNA has an

inherent 5' to 3' polarity, and transcription typically proceeds in a 5' to 3' fashion along the DNA strand. The promoter and enhancer elements which direct transcription of an operably linked coding region, or open reading frame, are generally located 5', or upstream, of the coding region. However, enhancer
5 elements can exert their effect even when located 3' of the promoter and coding region. Transcription termination and polyadenylation signals are typically located 3' or downstream of the coding region.

The 3' end of a promoter is said to be located upstream of the 5' end of a sequence-specific recombinase target site when, moving in a 5' to 3' direction
10 along the nucleic acid molecule, the 3' terminus of a promoter precedes the 5' end of the sequence-specific recombinase target site. When the acceptor construct is intended to permit the expression of a translation fusion, the 3' end of the promoter is located upstream of both the sequences encoding the amino-terminus of a fusion protein and the 5' end of the sequence-specific recombinase
15 target site. Thus, the sequence-specific recombinase target site is located within the coding region of the fusion protein (*i.e.*, located downstream of both the promoter and the sequences encoding the affinity domain, such as Gst).

As used herein, the term "adjacent", in the context of positioning of genetic elements in the constructs, shall mean within about 0 to 2500, sometimes 0 to
20 1000 bp and sometimes within about 0 to 500, 0 to 400, 0 to 300 or 0 to 200 bp.

A DNA "coding sequence" is a double-stranded DNA sequence that is transcribed and translated into a polypeptide *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a
25 translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (*e.g.*, mammalian) DNA, and even synthetic DNA sequences. A polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence. A "cDNA"
30 is defined as copy-DNA or complementary-DNA, and is a product of a reverse transcription reaction from an mRNA transcript. An "exon" is an expressed

sequence transcribed from the gene locus, whereas an "intron" is a non-expressed sequence that is from the gene locus.

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell. A "cis-element" is a nucleotide sequence, also termed a "consensus sequence" or "motif," that interacts with proteins that can upregulate or downregulate expression of a specific gene locus. A "signal sequence" can also be included with the coding sequence. This sequence encodes a signal peptide, N-terminal to the polypeptide, that communicates to the host cell and directs the polypeptide to the appropriate cellular location. Signal sequences can be found associated with a variety of proteins native to prokaryotes and eukaryotes.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence includes, at its 3' terminus, the transcription initiation site and extends upstream (in the 5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site, as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters often, but not always, contain "TATA" boxes and "CAT" boxes.

Efficient expression of recombinant DNA sequences in eukaryotic cells requires expression of signals directing the efficient termination and polyadenylation of the resulting transcript. Transcription termination signals are generally found downstream of the polyadenylation signal and are a few hundred nucleotides in length.

As used herein, "an origin of replication" or "origin" refers to any sequence capable of directing replication of a DNA construct in a suitable prokaryotic or eukaryotic host (e.g., the ColE1 origin and its derivatives; the yeast 2 μ origin). Eukaryotic expression vectors may also contain "viral replicons" or "origins of

replication". Viral replicons are viral DNA sequences which allow for the extrachromosomal replication of a vector in a host cell expressing the appropriate replication factors. Vectors which contain either the SV40 or polyoma virus origin of replication replicate to high copy number (up to 10^4 copies/cell) in cells that express the appropriate viral T antigen. Vectors which contain the replicons from bovine papillomavirus or Epstein-Barr virus replicate extrachromosomally at low copy number (~100 copies/cell).

As used herein, the terms "nucleic acid molecule encoding", "DNA sequence encoding", and "DNA encoding" refer to the order or sequence of deoxyribonucleotides along a strand of deoxyribonucleic acid. The order of these deoxyribonucleotides determines the order of amino acids along the polypeptide (protein) chain. The DNA sequence thus codes for the amino acid sequence.

As used herein, the term "gene" means the deoxyribonucleotide sequences comprising the coding region of a structural gene, i.e., the coding sequence for a protein or polypeptide of interest, including sequences located adjacent to the coding region on both the 5' and 3' ends for a distance of about 1 kb on either end, such that the gene corresponds to the length of the full-length mRNA. The sequences which are located 5' of the coding region and which are present on the mRNA are referred to as 5' non-translated sequences. The sequences which are located 3' or downstream of the coding region and which are present on the mRNA are referred to as 3' non-translated sequences. The term "gene" encompasses both cDNA and genomic forms of a gene. A genomic form or clone of a gene contains the coding region interrupted with non-coding sequences termed "introns" or "intervening regions" or "intervening sequences". Introns are segments of a gene that are transcribed into heteronuclear RNA (hnRNA); introns may contain regulatory elements such as enhancers. Introns are removed or "spliced out" from the nuclear or primary transcript; introns therefore are absent in the mature messenger RNA (mRNA) transcript. The mRNA functions during translation to specify the sequence or order of amino acids in a nascent polypeptide.

In addition to containing introns, genomic forms of a gene may also include sequences located on both the 5' and 3' end of the sequences that are present on the RNA transcript. These sequences are referred to as "flanking" sequences or regions (these flanking sequences are located 5' or 3' to the non-translated sequences present on the mRNA transcript). The 5' flanking region may contain regulatory sequences such as promoters and enhancers which control or influence the transcription of the gene. The 3' flanking region may contain sequences which direct the termination of transcription, post-transcriptional cleavage and polyadenylation.

As used herein, the term "purified" or "to purify" refers to the removal of contaminants from a sample. For example, recombinant Cre polypeptides are expressed in bacterial host cells (e.g., as a GST-Cre or (HN)₆-Cre fusion protein) and the Cre polypeptides are purified by the removal of host cell proteins; the percent of recombinant Cre polypeptides is thereby enriched or increased in the sample.

As used herein the term "portion" refers to a fraction of a sequence, gene or protein. "Portion" may comprise a fraction greater than half of the sequence, gene or protein, equal to half of the sequence, gene or protein or less than half of the sequence, gene or protein. Typically as used herein, two or more "portions" combine to comprise a whole sequence, gene or protein.

As used herein, the term "fusion protein" refers to a chimeric protein containing a protein of interest joined to an exogenous protein fragment. The fusion partner may enhance solubility of the protein of interest as expressed in a host cell, may provide an affinity tag to allow purification of the recombinant fusion protein from the host cell or culture supernatant, or both. If desired, the fusion protein may be removed from the protein of interest by a variety of enzymatic or chemical means known to the art.

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Methods are provided for producing a vector that includes at least one splicable intron. In the subject methods, intron containing vectors are produced

from donor and acceptor vectors that each include a site specific recombinase site, where the subject donor and acceptor vectors further include splice donor and acceptor sites that, upon site specific recombination of the donor and acceptor vectors, define an intron in the product vector of the recombination step.

- 5 Also provided are compositions for use in practicing the subject methods, including the donor and acceptor vectors themselves, as well as systems and kits that include the same. The subject invention finds use in a variety of different applications, including the production of expression vectors that encode C-terminal tagged fusion proteins, the production of expression vectors that encode
10 pure protein and not a fusion thereof, and the like.

Before the subject invention is described further, it is to be understood that the invention is not limited to the particular embodiments of the invention described below, as variations of the particular embodiments may be made and
15 still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present invention will be established by the appended claims.

20 In this specification and the appended claims, the singular forms "a," "an" and "the" include plural reference unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.

25 Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range, and any other stated or intervening value in that stated range, is encompassed within the invention.
30 The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention,

subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

5 Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. Although any methods, devices and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods, devices and materials are now
10 described.

All publications mentioned herein are incorporated herein by reference for the purpose of describing various invention components that are described in the publications which might be used in connection with the presently described
15 invention.

In further describing the subject invention, the subject methods are reviewed first in greater detail, followed by a review of representative applications in which the subject methods find use, as well as a review of systems, libraries
20 and kits for use in practicing the subject methods.

METHODS

As summarized above, the subject invention provides recombinase-based
25 methods for producing intron containing vectors. In other words, the subject invention provides methods of producing vectors that include at least one intron, where the methods are site specific recombinase based methods. By "site specific recombinase" based method is meant that the subject methods employ a recombinase mechanism to produce the subject intron containing vectors. The
30 recombinase mechanism that is employed in the subject methods is one in which a recombinase mediates the transfer of a nucleic acid from a donor to an

acceptor vector, where the donor and acceptor vectors each include at least one recombinase recognition site. A variety of different site specific recombinase systems suitable for transferring a nucleic acid from a donor to an acceptor vector are known and may be modified to be useful in the subject invention. Such systems include those described in U.S. Patent Nos. 5,851,808; 5,888,732; and U.S. Provisional Application Serial No. 09/616,651, the disclosure of which are herein incorporated by reference, as well as WO 00/12687 and WO 01/05961, the disclosures of the priority documents of which are herein incorporated by reference.

10 In general, in addition to each including at least one recombinase recognition site, the donor and acceptor vectors each include at least one splice site, e.g., a splice donor site or a splice acceptor site. In certain embodiments, the donor and acceptor vectors each include a single splice site, where in many of these embodiments, the donor vector includes a splice donor site and the
15 acceptor vector includes a splice acceptor site. In yet other embodiments, the donor and acceptor vectors each include splice donor and acceptor sites which are oriented such that they do not form an intron in the donor vectors but, upon recombinase mediated recombination of the donor and acceptor vectors, produce a resultant vector with two distinct introns. In such designs, the acceptors will
20 contain one synthetic intron that encompasses the recombinase recognition sequence and the acceptor partial selectable marker.

Any convenient splice sites (i.e., splice donor and acceptor sites) may be employed in the vectors of the subject method. Representative splice sites or sequences, e.g., domains, of interest that may be employed include both splice
25 sites that require specifically provided factors for splicing, e.g., eukaryotic host factors (as found in a eukaryotic host cells) such that the intron is only spliced in a eukaryotic host cell or an mimetic (e.g., in vivo or in vitro) environment that provides all the relevant factors, and splice sites that are self-splicing or autocatalytic, i.e., do not require specific factors for splicing to occur, and thus are
30 spliced in both eukaryotic and prokaryotic environments, as well as in vitro environments. Examples include the splicing elements of Group I and Group II

self-splicing introns found in bacteria, and certain cellular organelles, e.g., the highly conserved in Group I self-splicing intron, P7; the bacterial group II intron *L. lactis* L1.ltrB; the yeast mitochondrial group II introns al1 and al2; and the bacterial group II intron *Sinorhizobium meliloti* Rmlnt1 (see Oe Y., et al.,2001; and
5 Martínez-Abarca, F. and Toro, N., 2000)

Any convenient splice acceptor donor and acceptor sites may be employed. Consensus sequences for the 5' splice donor site and the 3' splice acceptor site used in RNA splicing are well known in the art (See, Moore, et al.,
10 1993, The RNA World, Cold Spring Harbor Laboratory Press, p. 303-358). In addition, modified consensus sequences that maintain the ability to function as 5' donor splice sites and 3' splice acceptors sites may be used in the practice of the invention. In certain embodiments, splice-donor sites have a characteristic consensus sequence represented as: (A/C)AGGURAGU (where R denotes a
15 purine nucleotide) with the GU in the fourth and fifth positions being required (Jackson, I. J., Nucleic Acids Research 19: 3715-3798 (1991)). Splice-donor sites are functionally defined by their ability to effect the appropriate reaction within the mRNA splicing pathway. An unpaired splice-donor site is defined herein as a splice-donor site which is present in a donor or acceptor vector, typically a donor
20 vector, and is not accompanied in the vector by a splice-acceptor site positioned 3' to the unpaired splice-donor site. Upon recombinase mediated recombination between the donor and acceptor vectors, the unpaired splice-donor site results in splicing to a splice-acceptor site originally present in the other vector. A splice-acceptor site is a sequence which, like a splice-donor site, directs the splicing of
25 an intron out of a resultant expression cassette produced upon recombinase mediated recombination of the donor and acceptor vectors. Acting in conjunction with a splice-donor site, the splicing apparatus uses a splice-acceptor site to effect the removal of an intron. Splice-acceptor sites have a characteristic sequence represented as: YYYYYYYYYNYAG, where Y denotes any pyrimidine
30 and N denotes any nucleotide (Jackson, I. J., Nucleic Acids Research 19:3715-3798 (1991)). For convenience, in the present embodiments, the splice acceptor

sequence is immediately preceded by the intron Branch site and these are considered here as one unit, although they may be separated. The consensus Branch site is: YNYYRAY, where Y denotes any pyrimidine, R any purine, and N denotes any nucleotide.

5 Specific splice sites of interest include, but are not limited to: (a) the novel consensus intron sequences and the Human hemoglobin Beta donor and acceptor sequences described in Liu Z. et al Anal Biochem 246: 264-267 (1997) and found in the experimental section, *infra*; (b) the donor and acceptor sequences found in the SV40 late 19s and 16s mRNA introns (see pCMV myc
10 from Clontech); (c) the splice donor and acceptor sequences found in the rabbit Beta globin intron (found in the vector pCMV-neo-Bam); and the like.

 The position of the splice donor and acceptor sequences in the various donor and acceptor vectors determines the location of the intron in the resultant product vector and, therefore, the domain that is spliced out of the resultant
15 vector under appropriate splicing conditions, e.g., in a eukaryotic host cell. Thus, by knowing how the acceptor and donor vectors recombine into a resultant vector, one can position the donor and acceptor splice sites in the donor and acceptor vectors to provide for an intron in any location of the resultant vector, and therefore removal of any sequence of the resultant vector. For example, the
20 donor and acceptor splice sites can be positioned to provide for a spliceable intron in the resultant product vector that includes the 3' recombinase recognized site, the 5' recombinase recognized site, etc. See, e.g., the experimental section below for more details with respect to a donor and acceptor vector system in which the donor and acceptor splice sites are positioned to provide for a resultant
25 vector in which the 3' recombinase site (lox) is present in a spliceable intron.

 In many embodiments of interest, the donor and acceptor vectors are further characterized in that one of the donor and acceptor vectors includes only one recombinase recognition site, while the other of the donor and acceptor vectors includes two recombinase recognition sites. As mentioned above, in many
30 embodiments, the donor vector includes two recombinase recognition sites while the acceptor vector includes a single recombinase recognition site. In an

alternative embodiment, the donor vector includes a single recombinase recognition site while the acceptor vector includes two recombinase recognition sites. Such a system is described in U.S. Application Serial No. 09/616,651, the disclosure of which is herein incorporated by reference.

5 A feature of the vectors of these embodiments is that the donor and acceptor vectors must be able to recombine in the presence of a suitable recombinase to produce an expression vector as described above, where the expression vector lacks at least a portion of the initial donor or acceptor vector, i.e., it is a non-fusion expression vector. As such, the donor and acceptor vectors
10 must be able to participate in a recombination event that is other than a fusion event, where by fusion event is meant an event in which two complete vectors are fused in their entirety into one fused vector, e.g., where two plasmids are fused together to produce one plasmid that includes all of material from the initial two plasmids, i.e., a fusion plasmid. As such, the subject methods of these particular
15 embodiments are not fusion methods, where such methods are defined as those methods in which a single vector is produced from two or more initial vectors in their entirety, such that all of the initial vector material of each parent vector, e.g., plasmid, is present in its entirety in the resultant fusion vector.

 The donor and acceptor vectors of these particular embodiments are
20 further characterized in that one of the donor and acceptor vectors includes only one recombinase recognition site, while the other of the donor and acceptor vectors includes two recombinase recognition sites. In a first preferred embodiment, the donor vector includes two recombinase recognition sites while the acceptor vector includes a single recombinase recognition site. In an
25 alternative embodiment, the donor vector includes a single recombinase recognition site while the acceptor vector includes two recombinase recognition sites. The donor and acceptor vectors of this first, preferred embodiment and this second, alternative embodiment, are described in greater detail below.

 The donor and acceptor vectors described generally above may be linear
30 or circular, e.g., plasmids, and in many embodiments of the subject invention are plasmids. Where the donor and acceptor vectors are plasmids, the donor and

acceptor vectors typically range in length from about 2 kb to 200 kb, usually from about 2 kb to 40 kb and more usually from about 2 kb to 10 kb.

The donor and acceptor vectors are further characterized in certain embodiments in that all of the recombinase recognition sites on the donor and acceptor vectors must be recognized by the same recombinase and should be able to recombine with each other, but within this parameter they may be the same or different, but in many embodiments are usually the same. Recombinase recognition sites, i.e., sequence-specific recombinase target sites, of interest include: Cre recombinase activity recognized sites, e.g., loxP, loxP2, loxP511, loxP514, loxB, loxC2, loxL, loxR, loxΔ86, loxΔ117; att, dif; frt; and the like. The particular recombinase recognition site is chosen, at least in part, based on the nature of the recombinase to be employed in the subject methods.

The Donor Vector

As mentioned above, in a preferred embodiment of the subject methods, the donor vector includes two recombinase recognition sites while the acceptor vector includes a single recombinase recognition site. In the donor vector of these embodiments, the donor vector includes two recombinase recognition sites, capable of recombining with each other, e.g., site 1A and site 1B, that flank or border a first or donor domain, i.e., desired donor fragment, where this domain is the portion of the vector that becomes part of the expression vector produced by the subject methods. The length of the donor domain may vary, but in many embodiments ranges from 1 kb to 200 kb, usually from about 1 kb to 10 kb. The portion of the donor vector that is not part of this donor domain, i.e., the part that is 5' of site 1A and 3' of site 1B, is referred to herein for clarity as the non-donor domain of the donor vector.

The two recombinase recognition sites of the donor vector are characterized in that they are oriented in the same direction and are capable of recombining with each other. By oriented in the same direction it is meant that

they have the same head to tail orientation. Thus, the orientation of site 1A is the same as the orientation of site 1B.

The donor domain flanked by the two recombinase recognition sites, i.e., the portion of the vector 3' of the first recombinase site 1A and 5' of the second recombinase site 1B, includes at least the following components: (a) at least one restriction site and (b) at least a portion of a selectable marker, e.g. a coding sequence, a promoter, or a complete selectable marker made up of a coding sequence and a promoter. The donor domain may include at least one restriction site or a plurality of distinct restriction sites, e.g., as found in a multiple cloning site or polylinker, where by restriction site is meant a stretch of nucleotides that has a sequence that is recognized and cleaved by a restriction endonuclease. Where a plurality of restriction sites are present in the donor domain, the number of distinct or different restriction sites typically ranges from about 2 to 5, usually from about 2 to 13.

In many embodiments, there are at least two restriction sites, which may or may not be identical depending on the particular protocol employed to produce the donor plasmid, that flank a nucleic acid which is a coding sequence for a protein of interest, where the protein of interest may or may not be known, e.g., it may be a known coding sequence for a known protein or polypeptide or a coding sequence for an as yet unidentified protein or polypeptide, such as where this nucleic acid of interest is a constituent of a library, as discussed in greater detail below. The length of this nucleic acid of interest nucleic acid may vary greatly, but generally ranges from about 18 bp to 20 kb, usually from about 100 bp to 10 kb and more usually from about 1 kb to 3 kb. At least one restriction site and this nucleic acid of interest nucleic acid, when present, are sufficiently close to the 3' end of the first flanking recombinase site, i.e., recombinase recognition site 1A, such that in the expression vector produced from the donor plasmid, expression of the coding sequence of the nucleic acid of interest is driven by a promoter positioned 5' of this first recombinase site. As such, the distance separating this restriction site/nucleic acid of interest nucleic acid from the recombinase site typically ranges from about 1 bp to 150 bp, usually from about 1 bp to 50 bp.

In a first preferred embodiment, the donor domain also generally includes a portion of a selectable marker. By portion of a selectable marker is meant a subpart of a selectable marker, e.g. a coding sequence or a promoter, which can be joined with a second subpart to produce a functioning selectable marker that confers some selectable phenotype on the host cell in which the expression vector produced by the subject methods is to be propagated. Examples of subparts of selectable markers are coding sequences and promoters. As such, in many embodiments, the portion of the selectable marker present on the donor domain is a coding sequence of a marker gene or a promoter capable of driving expression of the coding sequence of the marker gene, where in certain preferred embodiments, the coding sequence of a marker gene is the portion of the selectable marker present on the donor domain. Examples of coding sequences of interest include, but are not limited to, the coding sequences from the following marker genes: the chloramphenicol resistance gene, the ampicillin resistance gene, the tetracycline resistance gene, the kanamycin resistance gene, the streptomycin resistance gene and the SacB gene from *B. subtilis* encoding sucrase and conferring sucrose sensitivity; and the like. The promoter portions or sub-parts of this selectable marker are any convenient promoters capable of driving expression of the selectable marker in the expression vector produced by the subject methods, see *infra*, and in many embodiments are bacterial promoters, where particular promoters of interest include, but are not limited to: the Ampicillin resistance promoter, the inducible lac promoter, the tet-inducible promoter from pProTet (P_{tetO-1})- available from CLONTECH, T7, T3, and SP6 promoters; and the like. The distance of this sub-part or portion of the selectable marker from the 3' end of the second recombinase recognition site, i.e., site 1B, is sufficient to provide for expression of the marker to occur in the final expression vector, where the other part of selectable marker that is required for efficient expression of the selectable marker is present on the other side, i.e., the 5' side of the adjacent recombinase recognition site. This distance typically ranges from about 1 bp to 2.5 kb, usually from about 1 bp to 500 bp.

The length of the donor domain flanked by the first and second recombinase sites of the donor plasmid, i.e., the length of the desired donor fragment, may vary greatly, so long as the above described components are present on the donor domain. Generally, the length is at least about 100 bp, usually at least about 500 bp and more usually at least about 900 bp, where the length may be as great as 100 kb or greater, but generally does not exceed about 20 kb and usually does not exceed about 10 kb. Typically, the length of the donor domain ranges from about 100 bp to 100 kb, usually from about 500 bp to 20 kb and more usually from about 900 bp to 10 kb.

In addition to the above described components, the donor vector may include a number of additional elements, where desired, that are present on the non-donor domain or non-desired donor fragment of the donor vector. For example, the non-donor domain generally includes an origin of replication. This origin of replication may be any convenient origin of replication or ori site, where a number of ori sites are known in the art, where particular sites of interest include, but are not limited to: ColE1 and its derivatives, pMB1, other origins that function in prokaryotic cells, the yeast 2 micron origin and the like. Also present on this non-donor domain of certain preferred embodiments is a selective marker gene that provides for negative selection of the non-donor domain under particular conditions, e.g., negative selection conditions. This marker is fully functional and therefor is made up of a coding sequence operably linked to an appropriate promoter, i.e., is provided by a functional expression module or cassette. Markers of interest that are capable of providing for this negative selection include, but are not limited to: SacB, providing sensitivity to sucrose; ccdB; and the like.

This non-donor domain of the donor vector may further include one or more additional components or elements that impart additional functionality to the donor vector. For example, the donor vector may be a vector that is specifically designed for use in conjunction with a yeast two hybrid assay protocol, e.g., such that one can determine whether the gene of interest present in the donor domain encodes a product that binds to a second protein prior to transferal of the gene of interest to an expression vector. In such embodiments, the non-donor domain

typically includes the following additional elements: yeast origins of replication, e.g., the yeast 2 micron origin; yeast selection markers, e.g., URA3, Leu, and trp selection markers; and peptide fragments of yeast transcription factors that are expressed as translational fusions to the gene encoded within the donor-domain;

5 where yeast two hybrid systems are known to those of skill in the art and described in: Fields, S. and O-K. Song. 1989. A novel genetic system to detect protein-protein interactions. *Nature* **340**:245-246; Fields, S. and R. Sternglanz. 1994. The two-hybrid system: an assay for protein-protein interactions. *Trends Genet.* **10**: 286-292 and the MATCHMAKER system III user manual, available

10 from CLONTECH.

In other embodiments, the non-donor domain and/or donor domains may contain yet other functional elements that provide specific functions to the donor. For example, Donor vectors can be designed that would also function as prokaryotic expression vectors that express the gene of interest encoded on the

15 donor domain in prokaryotic cells either as a native protein or fused to an affinity or epitope tag. Such vectors may include the following elements in their non-donor or donor domains (e.g., 3' of the multiple cloning site): inducible bacterial promoters, such as the lac promoter or the P_{tetO-1} promoter; affinity or epitope tags, e.g., GST, 6x(HN), myc-tag, HA-Tag, GFP and its derivatives. Donor

20 vectors designed to function as retroviral vectors would additionally include retroviral LTRs and packaging signals in the non-donor domain. Donor vectors for expression in mammalian cells might also encode affinity or epitope tags, e.g., GST, 6x(HN), myc-tag, HA-Tag, GFP and its derivatives; and mammalian constitutive or inducible promoters, e.g., the CMV promoter, the tet-inducible

25 promoter, the TK promoter; viral promoters, e.g., T7, T3, SP6. In a preferred embodiment of this particular embodiment of the subject invention, the donor vector is as follows. The donor-partial selectable marker comprises the open reading frame (ORF) for a selectable marker gene, and is placed between the two donor sequence-specific recombinase target sites, adjacent to the second-donor

30 sequence-specific recombinase target site. In a more preferred embodiment of the donor construct, the open reading frame of the selectable marker is situated

such that its 5' to 3' orientation is opposite that of the two donor sequence-specific recombinase target sites.

In another embodiment of the donor construct, the donor construct is a closed circle (e.g., a plasmid or cosmid) comprising, in addition to the two donor sequence-specific recombinase target sites, the unique restriction site or polylinker and the selectable marker gene open reading frame, at least one origin of replication, and at least one donor-functional selectable marker gene. The methods of the present invention should not be limited by the origin of replication selected. For example, origins such as those found in the pUC series of plasmid vectors or of the pBR322 plasmid may be used, as well as others known in the art. Those skilled in the art know that the choice of origin depends on the application for which the donor construct is intended and/or the host strain in which the construct is to be propagated.

A variety of selectable marker genes may be utilized, either for the donor-partial selectable marker or for the donor-functional selectable marker, and such genes may confer either positive- or negative-resistance phenotypes; however, the donor-partial and the donor-functional selectable marker genes should be different from one another. In a preferred embodiment, the selectable markers are selected from the group consisting of the chloramphenicol resistance gene, the ampicillin resistance gene, the tetracycline resistance gene, the kanamycin resistance gene, the streptomycin resistance gene and the sacB gene from *B. subtilis* encoding sucrase and conferring sucrose sensitivity. In a more preferred embodiment, the donor-partial selectable marker is a portion of the gene (e.g., the open reading frame) for chloramphenicol resistance and the donor-functional selectable marker gene is the gene for ampicillin resistance. In another preferred embodiment of the donor construct, the origin of replication and the donor-functional selectable marker gene lie 5' of the first-donor sequence-specific recombinase target site.

In another embodiment of the present invention, there is provided a donor construct with all the above-described features, but additionally having a marker gene different from either the donor-functional selectable marker gene or the

donor-partial selectable marker gene, wherein the additional marker gene is positioned 5' of the first sequence-specific recombinase target site such that upon combination with a recombinase, the additional marker gene is located on the undesired second donor fragment. This marker gene provides an additional screen to exclude any products that result in recombinants containing the second donor fragment. The marker gene could be, for example, LacZ. In this case, incorrect recombinants would generate blue colonies on X-Gal plates.

Alternatively, a more preferred additional marker would be the sacB gene conferring sucrose sensitivity. In this case, any incorrect clones would be killed when grown on sucrose containing medium. The additional marker provides another screen, thereby enhancing the system by further ensuring that only correct recombination products are obtained following recombination and transformation.

In yet another embodiment of the donor construct, the donor construct further comprises a termination sequence placed 3' of the restriction site or polylinker sequence but 5' of the second-donor sequence-specific recombinase target site. In a most preferred embodiment, the termination sequence is placed 5' of the 3' end of the donor-partial selectable marker (e.g. the ORF of the selectable marker gene in the preferred embodiment which is in the 5' to 3' orientation opposite that of both donor sequence specific recombinase target sites). The present embodiment is not be limited by the termination sequence chosen. In one embodiment, the termination sequence is the T1 termination sequence; however, a variety of termination sequences are known to the art and may be employed in the nucleic acid constructs of the present invention, including the T6S, TINT, TL1, TL2, TR1, and TR2 termination signals derived from the bacteriophage lambda, and termination signals derived from bacterial genes such as the trp gene of *E. coli*.

In another preferred embodiment of the donor construct, the donor construct further comprises a polyadenylation sequence placed 3' of the unique restriction site(s) or polylinker but 5' of the second-donor sequence-specific recombinase target site. In a most preferred embodiment, the polyadenylation

sequence is placed 5' of the 3' end of the open reading frame of the selectable marker gene similar to the placement described for the termination sequence *supra*. The present invention should not be limited by the nature of the polyadenylation sequence chosen. In one embodiment, the polyadenylation sequence is selected from the group consisting of the bovine growth hormone polyadenylation sequence, the simian virus 40 polyadenylation sequence and the Herpes simplex virus thymidine kinase polyadenylation sequence.

Also, in a preferred embodiment, the donor construct further comprises a gene or DNA sequence of interest inserted into the unique restriction enzyme site or polylinker. The present invention should not be limited by the size of the DNA of interest inserted into the unique restriction site or polylinker nor the source of DNA (e.g., genomic libraries, cDNA libraries, etc.).

Thus, in a most preferred embodiment of the donor nucleic acid construct, there is provided, in 5' to 3' order: a) a first-donor sequence-specific recombinase target site; b) a nucleic acid or gene of interest; c) termination and polyadenylation sequences; d) an open reading frame for a selectable marker gene in a 5' to 3' orientation opposite to that of the first-donor sequence-specific recombinase target site; e) a second-donor sequence-specific recombinase target site in the same 5' to 3' orientation as the first donor sequence-specific recombinase target site, wherein the second-donor sequence-specific recombinase target site is able to recombine with said first-donor sequence-specific recombinase target site; f) an origin of replication; and g) a donor-functional selectable marker gene.

In addition to the above features, the donor vector also includes at least one splice site, e.g., a splice donor and/or splice acceptor site. Two representative and non-limiting embodiments are now reviewed. In certain embodiments, the donor vector includes a splice donor site that is positioned to provide for an intron flanking the 3' sequence specific recombinase site in the product vector. In these embodiments, the splice donor site is positioned between the 5' and 3' sequence specific recombinase sites and, more usually, 3' of the multiple cloning site or gene of interest and 5' of the second sequence specific recombinase site. These

embodiments find use in producing vectors that express the gene of interest as a C-terminal tagged fusion, as a product that does not include sequence encoded by the 3' sequence specific recombinase site, etc. In certain embodiments, the donor vector also includes a splice acceptor site that is immediately 3' of the 5' sequence specific recombinase site. Since the splice acceptor is 5' of the splice donor sites in the vector, the two splice sites do not make a spliceable intron in the donor vector. However, upon recombination with an appropriate acceptor vector, a product vector in which both the 5' and 3' sequence specific recombinase sites are present in distinct introns can be produced. These embodiments are useful in applications where one wishes to express a protein from the product vector in a manner that is free of any residues encoded by the 5' and 3' sequence specific recombinase sites.

The Acceptor Vector

As mentioned above, in a preferred embodiment of the subject invention, the acceptor vector employed in the subject methods is a vector that includes a single recombinase site. In these embodiments, the single recombinase site is flanked on one side by a promoter and on the other side, in certain preferred embodiments, by a portion of a selectable marker, e.g., a promoter or a coding sequence, where in many preferred embodiments described further below, this portion or sub-part of the selectable marker is a second promoter, e.g., a bacterial promoter. In these embodiments, the single recombinase site is flanked by two oppositely oriented promoters, where one of promoters drives expression of the gene of interest in the expression vector produced by the subject methods and the second promoter drives expression of the coding sequence of the recombinant-functional selectable marker in the expression vector produced by the subject methods. In these embodiments, the first promoter is a promoter that is capable of driving expression of the gene of interest in the expression vector, where representative promoters include, but are not limited to the CMV promoter, the tet-inducible promoter; retroviral LTR promoter/enhancer sequences, the TK

promoter, bacterial promoters, e.g. the lac promoter , the P_{LtetO-1} promoter; the yeast ADH promoter and the like. The distance between the first promoter and the recombinase site is one that allows for expression in the final expression vector, where the distance typically ranges from about 1 bp to 1000 bp, usually from about 10 bp to 500 bp. The second promoter is a promoter that is capable of driving expression of the recombinant-functional selectable marker, and is generally a bacterial promoter. Bacterial promoters of interest include, but are not limited to: the Ampicillin promoter, the lac promoter , the P_{LtetO-1} promoter , the T7 promoter and the like. The distance between the bacterial promoter and the recombinase site is sufficient to provide for expression of the selectable marker in the expression vector and typically ranges from about 1 bp to 2.5 kb, usually from about 1 bp to 200 bp.

As indicated above, in yet other preferred embodiments the acceptor vector lacks the portion or subpart of the selectable marker. In these embodiments, the acceptor vector may be used with a donor vector that includes a complete positive selectable marker in the desired donor fragment flanked by the two recombinase sites, i.e., the donor vector portion located between the 3' end of the first recombinase site and the 5' end of the second recombinase site. Alternatively, the acceptor vector may be used with a donor vector that only includes a partial selectable positive marker, as described above, where the partial marker is nonetheless functional in the resultant expression vector.

The acceptor vector of the embodiments described above may include a number of additional components or elements which are requisite or desired depending on the nature of the expression vector to be produced from the acceptor vector. In many embodiments of the subject invention, the acceptor vector is an acceptor nucleic acid construct comprising: a) an origin of replication capable of replicating the final desired recombination construct or expression vector; b) an acceptor sequence-specific recombinase target site having a defined 5' to 3' orientation; c) a first promoter adjacent to the 5' end of the acceptor sequence-specific recombinase target site; and d) an acceptor-partial selectable marker, wherein the acceptor-partial selectable marker is capable of

recombining with a donor-partial selectable marker from a donor construct (or first donor fragment, once the donor construct is resolved) so creating a recombinant-functional selectable marker in a final desired recombination construct. As in the donor construct, the acceptor construct is not limited by the nature of the sequence-specific recombinase target site employed, and in preferred embodiments the sequence-specific recombinase target site may be selected from the group consisting of loxP, loxP2, loxP511, loxP514, loxB, loxC2, loxL, loxR, loxΔ86, loxΔ117, loxP3, loxP23, att, dif, and frt. The acceptor sequence-specific recombinase target site from the acceptor construct does not have to be identical to those on the donor construct; however, the sequence-specific recombinase target sites on the acceptor and donor constructs must be able to recombine with each other.

In a preferred embodiment, the acceptor-partial selectable marker is a second promoter, wherein the second promoter is oriented such that its 5' to 3' orientation is opposite that of the acceptor sequence-specific recombinase target site and the first promoter, and wherein the 3' end of the second promoter is adjacent to the 3' end of the acceptor sequence-specific recombinase target site.

The acceptor construct is not limited by the nature of the origin of replication employed. A variety of origins of replication are known in the art and may be employed on the acceptor nucleic acid constructs of the present invention. Those skilled in the art know that the choice of origin depends on the application for which the acceptor construct is intended and/or the host strain in which the construct is to be propagated. In the case of the acceptor construct, the origin of replication is chosen appropriately such that both the acceptor construct and the final desired recombination construct will be able to replicate in the given host cell.

The acceptor construct also is not limited by the nature of the promoters employed. Those skilled in the art know that the choice of the promoter depends upon the type of host cell to be employed for expressing a gene(s) under the transcriptional control of the chosen promoter. A wide variety of promoters functional in viruses, prokaryotic cells and eukaryotic cells are known in the art

and may be employed in the acceptor nucleic acid constructs of the present invention. In a preferred embodiment of the invention, the donor construct contains a gene or DNA sequences of interest and when the donor construct recombines with the acceptor construct, the first promoter of the acceptor
5 construct is positioned such that it will drive expression of the gene or DNA sequences of interest. Thus, a promoter capable of driving the gene or DNA sequences of interest should be chosen for the first promoter. Further, in a preferred embodiment of the present invention, the acceptor-partial selectable marker is a promoter capable of driving the expression of the donor-partial
10 selectable marker ORF from the donor construct (*e.g.*, the promoter for the ampicillin gene from the plasmid pUC19) or a viral promoter including, but not limited to, the T7, T3, and Sp6 promoters.

In yet another preferred embodiment of the acceptor construct, the acceptor construct additionally includes a DNA sequence encoding a peptide
15 affinity domain or peptide tag sequence, wherein the affinity domain or tag sequence is 3' of the first promoter and 5' of the acceptor sequence-specific recombinase target site, such that the expression of the affinity domain or tag sequence is under control of the first promoter, and such that it is in the same translational frame as the acceptor sequence-specific recombinase target site.
20 The present invention is not limited by the nature of the affinity domain or tag sequence employed; a variety of suitable affinity domains are known in the art, including glutathione-S-transferase, the maltose binding protein, protein A, protein L, polyhistidine tracts, etc.; and tag sequences include, but are not limited to the c-Myc Tag, the HA Tag, the FLAG tag, Green Fluorescent Protein (GFP), etc.

25 In another preferred embodiment of the acceptor vector construct, the acceptor construct additionally includes a DNA sequence encoding a peptide affinity domain or peptide tag sequence, wherein the affinity domain or tag sequence is 3' of an intron splice acceptor sequence placed in the acceptor vector 3' of the partial selectable marker, such that when this vector is
30 recombined with a donor vector of the invention having an appropriately positioned intron splice donor sequence, an expression cassette is generated

having a functional synthetic intron and in which the expression of the affinity domain or tag sequence is under control of the first promoter of the acceptor vector, and such that it is in the same translational frame as a gene of interest placed within the donor vector. The present invention is not limited by the nature of the affinity domain or tag sequence employed; a variety of suitable affinity domains are known in the art, including glutathione-S-transferase, the maltose binding protein, protein A, protein L, polyhistidine tracts, etc.; and tag sequences include, but are not limited to the c-Myc Tag, the HA Tag, the FLAG tag, Green Fluorescent Protein (GFP), etc. Since this tag and the gene of interest are in-frame, following splicing, they will be expressed as a single fusion protein, with the Tag being at the C-terminus of the protein.

In another preferred embodiment of the acceptor construct, the acceptor construct further includes an acceptor-functional selectable marker. The present invention is not limited by the nature of the acceptor-functional selectable marker chosen and the selectable marker gene may result in positive or negative selection. In a preferred embodiment, the acceptor-functional selectable marker gene is selected from the group consisting of the chloramphenicol resistance gene, the ampicillin resistance gene, the tetracycline resistance gene, the kanamycin resistance gene, the streptomycin resistance gene and the sacB gene.

In addition to one or more of the above described components, the acceptor vectors may include a number of additional components that impart specific function to the expression vectors that are produced from the acceptor vector according to the subject methods. Additional elements that may be present on the subject acceptor vectors include, but are not limited to: (a) elements requisite for generating vectors suitable for use in yeast two hybrid expression assays, e.g., a GAL4 activation domain coding sequence, a GAL4 DNA-binding domain coding sequence, (as found in pLP-GADT7 and pLP-GBKT7 shown in Figs. 3A & 3B); (b) elements necessary for study of the localization of a protein in a cell, e.g., tagging elements such as fluorescent protein coding sequences, such as the GFP coding sequences; (c) elements necessary for constitutive, bicistronic

expression in mammalian cells, e.g., IRES sites, in combination with selectable markers, e.g. antibiotic resistance, fluorescent protein, etc. ; (d) elements necessary for inducible expression of the gene of interest on an expression vector, e.g. inducible promoters such as the tet-responsive promoter, etc.; (e)
5 elements that provide for retroviral expression vectors; and the like.

In addition to the above requisite and optional elements, the acceptor vectors further include at least one splice site. Two representative but non-limiting embodiments are now described further. In a first embodiment, the acceptor vector includes a splice acceptor site positioned 3' of the single sequence specific
10 recombinase site of the vector. More precisely, this splice acceptor sequence is placed 3' of the acceptor partial selectable marker sequence. This embodiment finds use in applications where one wishes to produce expression vectors in which the gene of interest is not expressed as a fusion with 3' sequence specific recombinase site encoded domains, etc. In a second representative
15 embodiment, the acceptor vector further includes a splice donor site which is positioned 5' of the single sequence specific recombinase site, where this embodiment finds use in those situations where one wishes to produce an expression vector in which the gene of interest is expressed as a protein that does not include either N or C-terminal residues encoded by the 5' and 3'
20 sequence specific recombinase sites.

Product Vector Generation with a Recombinase

As mentioned above, in the subject methods the donor and acceptor
25 vectors are contacted with a recombinase under conditions sufficient for site specific recombination to occur, specifically under conditions sufficient for a recombinase mediated recombination event to occur that produces the desired intron containing product vector, where product vector production is accomplished without cutting or ligation of the donor and acceptor vectors with restriction
30 endonucleases and nucleic acid ligases. The contact may occur under in vitro or in vivo conditions, as is desired and/or convenient.

In many embodiments, an aqueous reaction mixture is produced by combining the donor and acceptor vectors and the recombinase with water and other requisite and/or desired components to produce a reaction mixture that, under appropriate conditions, results in production of the desired expression vector. The various components may be combined separately or simultaneously, depending on the nature of the particular component and how the components are combined. Conveniently, the components of the reaction mixture are combined in a suitable container. The amount of donor and acceptor vectors that are present in the reaction mixture are sufficient to provide for the desired production of the expression vector product, where the amounts of donor and acceptor vector may be the same or different, but are in many embodiments substantially the same if not the same. In many embodiments, the amount of donor and acceptor vector that is present in the reaction mixture ranges from about 50 ng to 2 μ g, usually from about 100 ng to 500 ng and more usually from about 150 ng to 300 ng, for a reaction volume ranging from about 5 μ l to 1000 μ l, usually from about 10 μ l to 50 μ l.

The recombinase that is present in the reaction mixture is one that provides for recombination of the donor and acceptor vectors, i.e. one that recognizes the recombinase recognition sites on the donor and acceptor vectors. As such, the recombinase employed will vary, where representative recombinases include, but are not limited to: recombinases, transposes and integrases, where specific recombinases of interest include, but are not limited to: Cre recombinase (the cre gene has been cloned and expressed in a variety of hosts, and the enzyme can be purified to homogeneity using standard techniques known in the art-- purified Cre protein is available commercially from CLONTECH, Novagen, NEB, and others); FLP recombinase of *S. cerevisiae* that recognizes the frt site; Int recombinase of bacteriophage Lambda that recognizes the att site; xerC and xerD recombinases of *E.coli*, which together form a recombinase that recognizes the dif site. the Int protein from the Tn916 transposon; the Tn3 resolvase, the Hin recombinase; the Cin recombinase; the immunoglobulin recombinases; and the like. While the amount of recombinase present in the

reaction mixture may vary depending on the particular recombinase employed, in many embodiments the amount ranges from about 0.1 units to 1250 units, usually from about 1 unit to 10 units and more usually from about 1 unit to 2 units, for the above described reaction volumes. The aqueous reaction mixture may include
5 additional components, e.g., a reaction buffer or components thereof, e.g., buffering compounds, such as Tris-HCl; MES; sodium phosphate buffer, sodium acetate buffer; and the like, which are often present in amounts ranging from about 10 mM to 100 mM, usually from about 20 mM to 50 mM; monovalent ions, e.g., sodium, chloride, and the like, which are typically present in amounts
10 ranging from about 10 mM to 500 mM, usually from about 30 mM to 150 mM; divalent cations, e.g., magnesium, calcium and the like, which are often present in amounts ranging from about 1 mM to 20 mM, usually from about 5 mM to 10 mM; and other components, e.g., BSA, EDTA, spermidine and the like; etc (where the above amount ranges are provided for the representative reaction volumes
15 described above). As the reaction mixtures are aqueous reaction mixtures, they also include water.

The subject reaction mixtures are typically prepared at temperatures ranging from about 0-4°C, e.g., on ice, to minimize enzyme activity. Following reaction mixture preparation, the temperature of the reaction mixture is typically
20 raised to a temperature that provides for optimum or maximal recombinase activity, and concomitantly expression vector production. Often, in this portion of the method the temperature will be raised to a temperature ranging from about 4 °C to 37 °C, usually from about 10 °C to 25 °C , where the mixture will be maintained at this temperature for a period of time sufficient for the desired
25 amount of expression vector production to occur, e.g., for a period of time ranging from about 5 mins to 60 mins, usually from about 10 mins to 15 mins. Following the incubation period, the reaction mixture is subjected to conditions sufficient to inactivate the recombinase, e.g., the temperature of the reaction mixture may be raised to a value ranging from about 65 °C to 70 °C for a period of time ranging
30 from about 5 mins to 10 mins.

Alternatively, contact of the donor and acceptor vectors with the recombinase may occur *in vivo*, where the donor and acceptor vectors are introduced in a suitable host cell that expresses a recombinase. In this embodiment, the recombination between the donor and acceptor vectors may be accomplished *in vivo* using a host cell that transiently or constitutively expresses the appropriate site-specific recombinase (e.g., Cre recombinase expressed in the bacterial strain BNN132, available from CLONTECH). pDonor and pAcceptor, i.e., the donor and acceptor vectors respectively, are co-transformed into the host cell using a variety of methods known in the art (e.g., transformation of cells made competent by treatment with CaCl_2 , electroporation, etc.). The co-transformed host cells are grown under conditions which select for the presence of the recombinant-functional selectable marker created by recombination of pDonor with the pAcceptor (e.g., growth in the presence of chloramphenicol and sucrose when the pDonor vector contains the SacB negative selection marker on the non donor fragment and all or part of the chloramphenicol resistance gene open reading frame and pAcceptor may also contain a promoter necessary for expression of the chloramphenicol open frame). Plasmid DNA is isolated from host cells which grow in the presence of the selective pressure and is subjected to restriction enzyme digestion to confirm that the desired recombination event has occurred.

The present invention also provides a method for the *in vitro* recombination of nucleic acid constructs, comprising the steps of: a) providing i) a donor nucleic acid construct comprising a donor-partial selectable marker, two donor sequence-specific recombinase target sites each having a defined 5' to 3' orientation and wherein the donor sequence-specific recombinase target sites are placed in the donor construct such that they have the same 5' to 3' orientation, and a unique restriction enzyme site or polylinker, the restriction enzyme site or polylinker being located 3' of the first-donor sequence-specific recombinase target site and 5' of the second-donor sequence-specific recombinase target site; (ii) an acceptor nucleic acid construct comprising an origin of replication, an acceptor sequence-specific recombinase target site having a defined 5' to 3' orientation, a first

promoter adjacent to the 5' end of the acceptor sequence-specific recombinase target site, and an acceptor-partial selectable marker, wherein the acceptor-partial selectable marker is capable of recombining with the donor-partial selectable marker from the donor construct to create a recombinant-functional selectable marker in a final desired recombination construct; b) contacting the donor and acceptor constructs *in vitro* with a site-specific recombinase under conditions such that the desired donor fragment recombines with the acceptor construct to form a final desired recombination construct.

The present invention further provides a method for the recombination of nucleic acid constructs in a host, comprising the steps of: a) providing i) a donor nucleic acid construct comprising a donor-partial selectable marker, two donor sequence-specific recombinase target sites each having a defined 5' to 3' orientation and wherein the donor sequence-specific recombinase target sites are placed in the donor construct such that they have the same 5' to 3' orientation, and a unique restriction enzyme site or polylinker, the restriction enzyme site or polylinker located 3' of the first-donor sequence-specific recombinase target site and 5' of the second-donor sequence-specific recombinase target site; (ii) an acceptor nucleic acid construct comprising an origin of replication, an acceptor sequence-specific recombinase target site having a defined 5' to 3' orientation, a first promoter adjacent to the 5' end of the acceptor sequence-specific recombinase target site, and an acceptor-partial selectable marker, wherein the acceptor-partial selectable marker is capable of recombining with the donor-partial selectable marker from the donor to create a recombinant-functional selectable marker in a final desired recombination construct; and iii) a host cell expressing a site-specific recombinase; b) introducing the donor and acceptor constructs into the host cell under conditions such that the desired donor fragment recombines with the acceptor construct to form the final desired recombination construct which is capable of imparting the ability to the host cell to grow in selective growth medium.

The above methods of producing expression vectors can be employed to rapidly produce a plurality of different expression vectors that are distinct from

each other but carry the same coding sequence of interest from a single, original type of donor vector. In other words, the subject methods can be used to rapidly clone a nucleic acid of interest from an initial vector into a plurality of expression vectors. By plurality is meant at least 2, usually at least 5, and more usually at least 10, where the number may be as high as 20, 96 or more. The methods can be performed by one person in a period of time that is a fraction of what it would take by that person of skill in the art to produce the same number and variety of expression vectors using traditional cutting and ligation protocols, where the increase in efficiency obtained by the subject methods is at least about 6 fold, usually at least about 15 fold and more usually at least about 30 fold.

The Resultant Product Vector

The above steps result in the production of an intron containing product vector (i.e. a vector that includes one or more, e.g., one or two, spliceable introns) from donor and acceptor vectors, and in certain embodiments from a portion of one of these vectors and the entirety of the other of these vectors, e.g., from a portion of the donor vector and the entirety of the acceptor vector, where by portion is meant the part of the donor vector that lies 3' of the first donor sequence-specific recombinase site and 5' of the second donor sequence-specific recombinase site. The size of the product vector may vary, depending on the nature of the vector. Where the vector is a plasmid, the size of the expression vector may range from about 3 kb to 20 kb, usually from about 4 kb to 8 kb.

The resultant product vector in many embodiments is characterized in that it includes two recombinase recognition sites, i.e., a first and second recombinase recognition site, oriented in the same direction. The distance between the first and second recombinase sites, specifically the distance between the 3' end of the first recombinase site and the 5' end of the second recombinase site, ranges in many embodiments from about 100 bp to 100 kb, usually from about 500 bp to 20 kb, depending on whether the coding sequence of a protein of interest or just a restriction site/multiple cloning site, is present between the first and second

recombinase recognition sites. The portion of the vector that lies in this inter recombinase region, i.e. 3' of the first recombinase site and 5' of the second recombinase site, typically makes up from about 2 % to 85%, usually from about 20% to 60 % of the entire expression vector.

5 In many embodiments, the expression vector is further characterized in that 5' of the first recombinase site is a first promoter, 3' of the first recombinase site is at least one restriction site; and the second recombinase site located inside a functional selectable marker, i.e., it is flanked by disparate portions or sub-parts of a selectable marker expression module or cassette (e.g., a promoter and a
10 coding sequence), where the second recombinase site is present between the two sub-parts of the selectable marker in a manner such that the selectable marker is functional, i.e., the coding sequence of the selectable marker is expressed. In other words the expression vector includes a selectable marker expression cassette or module made up of a promoter and coding sequence that
15 flank the second recombinase site. In many embodiments, the second recombinase site is flanked by a promoter on its 3' end and a coding sequence of the selectable marker on its 5' end. In this embodiment, the first and second promoters, located 5' of the first recombinase site and 3' of the second recombinase site, respectively, are oriented in opposite directions.

20 The expression vector is further characterized by having at least one restriction site, and generally a multiple cloning site, located between the first and second recombinase sites. In many embodiments, located between the first and second recombinase sites, and flanked by two restriction sites, which may or may not be the same, is a nucleic acid of interest, i.e., gene of interest, that includes a
25 coding sequence for a protein of interest whose expression from the expression vector is desired. In these embodiments, the first promoter 5' of the first recombinase site and the coding sequence for the protein of interest are arranged on either side of the first recombinase site such that they form an expression module or cassette that expresses the encoded protein, i.e., the coding sequence
30 and first promoter flank the first recombinase site in manner such that they are operably linked.

10055794.01709
3047046500

5 In addition to the above features, the expression vector further includes at least one origin of replication that provides for replication in the host or hosts into which it is placed or transformed during use. Origins of replication of interest include, but are not limited to, those described above in connection with the donor and acceptor vectors.

10 In certain embodiments, the product vector contains a gene or DNA sequence of interest inserted into the unique restriction enzyme site or polylinker such that the gene or DNA sequence of interest is under the control of the first promoter. The gene or DNA sequence of interest is joined to the 3' end of the first-recombinant sequence-specific recombinase target site such that a functional transcriptional unit is formed so that the gene or DNA sequence of interest is expressed as a protein driven by the first promoter of the acceptor construct. In a more preferred embodiment, the gene of interest is joined to the 3' end of the first-recombinant sequence-specific recombinase target site such that a functional translational reading frame is created wherein the gene or DNA sequence of interest is expressed as a fusion protein with an affinity domain or tag sequence derived from the acceptor plasmid and under the expression control of the first promoter of the acceptor construct.

20 In another preferred embodiment, the gene of interest is joined to the donor splice site such that when the intron is spliced out of the resultant mRNA, the gene of interest is fused in frame to a C-terminal tag derived from the acceptor vector.

25 In certain embodiments, the product vector further comprises an acceptor-functional selectable marker gene derived from the acceptor construct. If an acceptor-functional selectable marker gene is present in addition to the newly-created recombinant-functional selectable marker, the acceptor-functional selectable marker is a different selectable marker from the newly-created recombinant-functional selectable marker. The present invention should not be limited by the nature of the selectable marker genes chosen; the marker genes may result in positive or negative selection and may be chosen from the group including, but not limited to, the chloramphenicol resistance gene, the ampicillin

30

resistance gene, the tetracycline resistance gene, the kanamycin resistance gene, the streptomycin resistance gene, the strA gene and the sacB gene.

In addition to the above features, the product vector further includes at least one, and typically one to two, spliceable introns. The one or more introns may be positioned anywhere in the product vector. In certain representative embodiments, the 3' recombinase recognized site is present in an intron. In other representative embodiments, the 5' recombinase recognized site is present in an intron. In yet other representative embodiments, both the 5' and 3' recombinase recognized sites are present in introns.

UTILITY

The subject methods find use in a variety of different applications, where such applications are generally those protocols and methods in which the transfer of a nucleic acid of interest from one vector to another, e.g., the cloning of a nucleic acid from an initial vector into a final vector, is desired. As such, the subject methods are particularly suited for use in cloning nucleic acids of interest, including whole libraries, from an initial vector into an expression vector, where the product vector may be functionalized to express the polypeptide or protein encoded by the nucleic acid of interest located on it in a variety of different desired environments and/or under desired conditions, e.g., in a cell of interest, in response to a particular stimulus, tagged by a detectable marker, etc.

As such, the product vectors produced by the subject methods find use in a variety of different applications, including the study of polypeptide and protein function and behavior, i.e., in the characterization of a polypeptide or protein, either known or unknown; and the like. In the broadest sense, the subject methods find application in any method where traditional digestion and ligation protocols are employed to transfer or clone a nucleic acid from one vector to another, e.g., cloning digestion and ligation protocols, where the expression vectors produced by the subject methods find use in research applications, as

well as other applications, e.g., protein production applications, therapeutic applications, and the like.

Depending on the location of the one or more introns in the product vectors, the product vectors find use in the expression of non-fusion proteins, e.g., proteins free of residues at their N- and C-termini that are encoded by sequence specific recombinase sites; N-and or C-termini tagged proteins, etc.

SYSTEMS

Also provided are systems for use in practicing the subject methods. The subject systems at least include a donor vector and an acceptor vector as described above. In addition, the subject systems may include a recombinase which recognizes the recombinase sites present on the donor and acceptor vectors. The systems may also include, where desired, a host cell, e.g., in in vivo methods of expression vector production, as described above. Other components of the subject systems include, but are not limited to: reaction buffer, controls, etc.

LIBRARIES

Also provided are nucleic acid libraries cloned into donor and/or acceptor vectors of the subject invention. These nucleic acid libraries are made up of a plurality of individual donor/acceptor vectors where each distinct constituent member of the library has a different nucleic acid portion or component, e.g., genomic fragment, cDNA, of an original whole nucleic acid library, i.e., fragmented genome, cDNA collection generated from the total or partial mRNA of an mRNA sample, etc. In other words, the libraries of the subject invention are nucleic acid libraries cloned into donor or acceptor vectors according to the subject invention, where the nucleic acid libraries include, but are not limited to, genomic libraries, cDNA libraries, etc. Specific donor/acceptor libraries of interest include, but are not limited to: Human Brain Poly A+ RNA; Human Heart Poly A+

RNA; Human Kidney Poly A+ RNA; Human Liver Poly A+ RNA; Human Lung Poly A+ RNA; Human Pancreas Poly A+ RNA; Human Placenta Poly A+ RNA; Human Skeletal Muscle Poly A+ RNA; Human Testis Poly A+ RNA; Human Prostate Poly A+ RNA and the like. With donor libraries according to the subject invention, the subject methods permit the rapid exchange of either individual clones of interest, groups of clones or potentially an entire cDNA library to a variety of expression vectors.

KITS

Also provided are kits for use in practicing the subject methods. The subject kits at least include at least one donor vector and a recombinase that recognizes the recombinase sites of the donor vector. The subject kits may further include other components that find use in the subject methods, e.g., acceptor vectors; reaction buffers, positive controls, negative controls, etc.

In addition to the above components, the subject kits will further include instructions for practicing the subject methods. These instructions may be present in the subject kits in a variety of forms, one or more of which may be present in the kit. One form in which these instructions may be present is as printed information on a suitable medium or substrate, e.g., a piece or pieces of paper on which the information is printed, in the packaging of the kit, in a package insert, etc. Yet another means would be a computer readable medium, e.g., diskette, CD, etc., on which the information has been recorded. Yet another means that may be present is a website address which may be used via the internet to access the information at a removed site. Any convenient means may be present in the kits.

The following examples are offered by way of illustration and not by way of limitation.

EXPERIMENTAL

Example 1. Representative Protocols

5

A.

Figure 5 provides a flow diagram of a representative recombinase based method according to the subject invention.

10 B.

In order to test the utility of intron-splicing to enable tagging of a protein of interest in a donor vector with a peptide tag or protein in an acceptor vector, a Donor and Acceptor vector capable of splicing were built using standard molecular biology techniques. The Donor vector was called pDNR-Dual. A map of this vector is provided in Figure 1 and its sequence is provided below as SEQ ID NO:01. The Acceptor vector was called pLPS-EGFP. A map of this vector is provided in Figure 2 and its sequence is provided below as SEQ ID NO:02. Further, a luciferase test gene was cloned, using standard techniques into the MCS of pDNR-Dual at the Sall and Apa I sites, so as to generate pDNR-Dual-Luc. A map of this vector is provided in Figure 3 and the sequence of this vector is provided below as SEQ ID NO:03. In so doing, the Luciferase gene was placed such that it had no stop codon and such that it would be in-frame with the EGFP tag present in pLPS-EGFP following Cre/Lox-based transfer from the Donor to the Acceptor.

25 The pDNR-Dual-Luc and pLPS-EGFP vectors were then recombined in vitro using Cre according to methods described in Clontech's Creator User Manual (Clontech Laboratories Inc., Palo Alto CA) (see also the methods disclosed in U.S. Application Serial No. 09/616,651, the disclosure of which is herein incorporated by reference), and an aliquot of the reaction was transformed
30 in to competent E. coli. Following selection on chloramphenicol and sucrose plates, recombinant clones were isolated and confirmed by standard restriction

mapping and sequencing to encode the expected recombinant molecule, having the luciferase gene from the donor vector transferred to the acceptor vector. This vector is called pLPS-Luc-EGFP. A map of this vector is provided in Figure 4 and the sequence of this vector is provided below as SEQ ID NO:04. This construct thus has both a splice donor sequence, provided from the donor vector, and a splice acceptor sequence, provided by the acceptor vector. Together, these create an artificial intron between the 3' end of the luciferase gene and the 5' end of the EGFP Tag. This intron being composed of the chloramphenicol open reading frame, the second LoxP site, and the ampicillin promoter sequence.

To test if this construct would generate a properly spliced mRNA, so enabling expression of a luciferase EGFP fusion protein, the pLPS-Luc-EGFP vector was then transfected into HEK293 cells using standard procedures known to the art. For comparison, the HEK293 cells were also transfected with a pLuc-EGFP construct. This construct was made by cloning the luciferase gene (without stop codon) in-frame with EGFP into the pEGFP-N1 vector (available from Clontech Laboratories, Inc. Palo Alto CA) using standard molecular biology techniques.

Twenty-four hours after transfection, the cells were examined for EGFP fluorescence using a fluorescence microscope. Both the splicing construct (pLPS-Luc-EGFP) and the direct luciferase-EGFP fusion (pLuc-EGFP) showed equivalent EGFP expression over untransfected control cells.

Extracts of the cells were then made and analyzed by western blotting using an anti-luciferase antibody. Again, both the splicing construct (pLPS-Luc-EGFP) and the direct luciferase-EGFP fusion (pLuc-EGFP) showed equivalent expression of the luciferase-EGFP fusion protein. A further analysis of total RNA extracted from cells transfected with the splicing construct (pLPS-Luc-EGFP) by Northern blotting, demonstrated that the mRNA generated from the construct was being efficiently spliced to remove the chloramphenicol sequences.

Example 2. Vector Sequence Information

A. pDNR-dual

5 1 gcgggccgcat aacttcgtat agcatacatt atacgaagtt atcagtcgac ggtaccggac
61 atatgcccgg gaattcctgc aggatccgct cgagaagctt tctagaccat tcgtttggcg
121 cgcggggcca ggtgagtggc cataatcata atcataatca taatcataat cacaactagc
181 ctaggagatc ctggtcatga ctagtgcttg gattctcacc aataaaaaac gcccgggcggc
241 aaccgagcgt tctgaacaaa tccagatgga gttctgaggt cactactgga tctatcaaca
10 301 ggagtccaag cgagctcgat atcaaattac gccccgccct gccactcatc gcagtactgt
361 tgaattcat taagcattct gccgacatgg aagccatcac aaacggcatg atgaacctga
421 atcgccagcg gcatcagcac cttgtcgccct tgcgtataat atttgcccat ggtgaaaacg
481 ggggcgaaga agttgtccat attggccacg tttaaatcaa aactggtgaa actcaccacg
541 ggattggctg agacgaaaaa catattctca ataaaccctt tagggaaata ggccaggttt
15 601 tcaccgtaac acgccacatc ttgcgaatat atgtgtagaa actgccggaa atcgctcgtg
661 tattcactcc agagcgatga aaacgtttca gtttgctcat ggaaaacggg gtaacaaggg
721 tgaacactat cccatatcac cagctcaccg tctttcattg ccatacgaat tccggatga
781 gcattcatca ggcgggcaag aatgtgaata aaggccggat aaaacttgtg cttatttttc
841 tttacggtct ttaaaaagcg cgtaatatcc agctgaacgg tctggttata ggtacattga
20 901 gcaactgact gaaatgcctc aaaatgttct ttacgatgcc attgggatat atcaacgggtg
961 gtatatccag tgattttttt ctccatttta gcttccttag ctccgaaaag atccataact
1021 tcgtatagca tacattatac gaagtattgc ggccgcgacg tccacatata cctgcccgtt
1081 actattatct agtgaaatga gatattatga tttttctga attgtgatta aaaaggcaac
1141 tttatgcca tgcaacagaa actataaaaa atacagagaa tgaaaagaaa cagatagatt
25 1201 ttttagttct ttaggcccgt agtctgcaaa tctttttatg attttctatc aaacaaaaga
1261 ggaaaataga ccagttgcaa tccaaacgag agtctaatag aatgaggtcg aaaagtaaat
1321 cgcgcgggtt tgttactgat aaagcaggca agacctaaaa tgtgtaaagg gcaaagtgtg
1381 tactttggcg tcacccctta catatttttag gtcttttttt attgtgctga actaacttgc
1441 catcttcaaa caggaggggt ggaagaagca gaccgctaac acagtacata aaaaggaga
30 1501 catgaacgat gaacatcaaa aagtttgcaa aacaagcaac agtattaacc ttactaccg
1561 cactgctggc aggaggcgca actcaagcgt ttgcgaaaga aacgaaccaa aagccatata
1621 aggaaacata cggcatttcc catattacac gccatgatat gctgcaaatc cctgaacagc
1681 aaaaaaatga aaaatatcaa gttcctgagt tcgattcgtc cacaattaaa aatatctctt
1741 ctgcaaaagg cctggacggt tgggacagct ggccattaca aaacgctgac ggcactgtcg
35 1801 caaactatca cggctaccac atcgtctttg cattagccgg agatcctaaa aatgcccgat
1861 acacatcgat tatcatgttc tatcaaaaag tcggcgaaac ttctattgac agctggaaaa
1921 acgctggccg cgtcttttaa gacagcgaca aattcgatgc aatgattct atcctaaaag
1981 accaaacaca agaatgggtc gggtcagcca catttacatc tgacggaaaa atccgtttat
2041 tctacactga tttctccggt aaacattacg gcaaacaaac actgacaact gcacaagtta
40 2101 acgtatcagc atcagacagc tctttgaaca tcaacgggtg agaggattat aaatcaatct
2161 ttgacggtga cggaaaaacg tatcaaaatg tacagcagtt catcgatgaa ggcaactaca
2221 gctcaggcga caaccatacg ctgagagatc ctactacgt agaagataaa ggccacaaat
2281 acttagtatt tgaagcaaac actggaactg aagatggcta ccaaggcgaa gaatctttat
2341 ttaacaaagc atactatggc aaaagcacat cattcttccg tcaagaaagt caaaaaactt
45 2401 tgcaaagcga taaaaaacgc acggctgagt tagcaaacgg cgctctcggt atgattgagc
2461 taaacgatga ttacacactg aaaaaagtga tgaaaccgct gattgcatct aacacagtaa
2521 cagatgaaat tgaacgcgcg aacgtcttta aaatgaacgg caaatggtag ctgttccactg
2581 actcccgcg atcaaaaatg acgattgacg gcattacgtc taacgatatt tacatgcttg
50 2641 gttatgtttc taattcttta actggcccat acaagccgct gaacaaaact ggccttgtgt
2701 taaaaatgga tcttgatcct aacgatgtaa cctttactta ctacacttcc gctgtacctc
2761 aagcgaaagg aaacaatgtc gtgattacaa gctatatgac aaacagagga ttctacgcag
2821 acaaacaatc aacgtttgcg cctagcttcc tgctgaacat caaaggcaag aaaacatctg
2881 ttgtcaaaga cagcatcctt gaacaaggac aattaacagt taacaaataa aaacgcaaaa

B, F & F Ref: CLON-069

Clontech Ref: P-90

F:\DOCUMENT\CLON\069\patent application.doc

5

10

15

20

25

30

35

2941 gaaaatgccg atatacctatt ggcattgacg tcaggtggca cttttcggggg aaatgtgcgc
3001 ggaaccccta tttgttttatt tttctaaata cattcaaata tgtatccgct catgagacaa
3061 taaccctgat aaatgcttca ataataattga aaaaggaaga gtatgagtat tcaacattttc
3121 cgtgtcgcgc ttattccctt ttttgcgga ttttgccctc ctgtttttgc tcaccagaa
3181 acgctggtga aagtaaaaga tgctgaagat cagttgggtg cagcagtggtg ttacatcgaa
3241 ctggatctca acagcggtaa gatccttgag agttttcgcc ccgaagaacg ttttccaatg
3301 atgagcactt ttaaagttct gctatgtggc gcggtattat cccgtattga cgccgggcaa
3361 gagcaactcg gtcgcgcgat acactattct cagaatgact tggttgagta ctcaccagtc
3421 acagaaaagc atcttacgga tggcatgaca gtaagagaat tatgcagtg ctcaccataacc
3481 atgagtgata aactgcggc caacttactt ctgacaacga tcggaggacc gaaggagcta
3541 accgctttttt tgcacaacat gggggatcat gtaactcgcc ttgatcgttg ggaaccggag
3601 ctgaatgaag ccataccaaa cgacgagcgt gacaccacga tgctgtagc aatggcaaca
3661 acgttgcgca aactattaac tggcgaaacta cttactctag cttcccgga acaattaata
3721 gactggatgg aggcggataa agttgcagga ccacttctgc gtcggccct tccggctggc
3781 tggtttattg ctgataaate tggagccggt gagcgtgggt ctgcggtat cattgcagca
3841 ctggggccag atggtaaagc ctcccgatc gtagtattct acacgacggg gagtcaggca
3901 actatggatg aacgaaatag acagatcgct gagatagtg cctcactgat taagcattgg
3961 taactgtcag accaagttta ctcatatata ctttagattg attttaaact tcatttttaa
4021 tttaaaagga tctaggtgaa gatcctttttt gataatctca tgaccaaact cccttaacgt
4081 gagttttcgt tccactgagc gtcagacccc gtagaaaaga tcaaaggatc ttcttgagat
4141 cttttttttt tgcgcgtaat ctgctgcttg caaacaaaaa aaccacgct accagcggg
4201 gtttggttgc cggatcaaga gctaccaact ctttttccga aggttaactg cttcagcaga
4261 gcgcagatac caaatactgt tcttctagt tagccgtagt taggccacca cttcaagaac
4321 tctgtagcac cgcctacata cctcgctctg ctaatcctgt taccagtggc tgctgccagt
4381 ggcgataagt cgtgtcttac cgggttgag tcaagacgat agttaccgga taaggcgcag
4441 cggtcgggct gaacggggggg ttcgtgcaca cagcccagct tggagcgaac gacctacacc
4501 gaactgagat acctacagcg tgagctatga gaaagcgcca cgcttccga agggagaaag
4561 gcggacaggt atccggtaag cggcaggggc ggaacaggag agcgcacgag ggagcttcca
4621 gggggaaaac cctggtatct ttatagtcct gtcgggtttc gccacctctg acttgagcgt
4681 cgatttttgt gatgctcgtc agggggggcg agcctatgga aaaacgccag caacgcggcc
4741 tttttacggt tccctggcct ttgctggcct tttgctcaca tgttctttcc tgcgttatcc
4801 cctgattctg tggataaccg tattaccgcc ttacgcgtgt aaaacgacgg ccagtagatc
4861 tgtaatacga ctcactatag ggcgctagct gctcgccga gccgaacgac cgagcgcagc
4921 gagtcagtga gcgaggaa (SEQ ID NO:01)

B. pLPS-EGFP

40

45

50

1 tagttattaa tagtaatcaa ttacgggggc attagttcat agcccatata tggagttccg
61 cgttacataa cttacggtaa atggcccgcg tggctgaccg cccaacgacc cccgcccatt
121 gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca
181 atgggtggag tatttacggg aaactgccc cttggcagta catcaagtgt atcatatgcc
241 aagtagcccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta
301 catgacctta tgggactttc ctacttgga gtacatctac gtattagtca tcgctattac
361 catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg
421 atttccaagt cttccacca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg
481 ggactttcca aaatgtcgta acaactcgc cccattgacg caaatgggag gtaggcgtgt
541 acgggtggag gtctatataa gcagagctgg tttagtgaac cgtcagatcc ctagcataa
601 ctctgtatag catacattat acgaagtatt agatccaata ttattgaagc atttatcagg
661 gttattgtct catgagcgga tacatatttg aatgtattta gaaaaataaa caaatagggg
721 ttccgcgcac atttccccga aaagtgccac ctgacgtgga tctcgagctc aagcttcgaa
781 ttcagggttt ccttgacaat atcatactta tctgtccct tttttttcca cagctaccgg
841 tcgcgagcaa gggcgaggag ctgttcaccg ggggtggtgcc catcctggtc gagctggacg
901 gcgacgtaaa cggccacaag ttcagcgtgt ccggcgaggg cgagggcgat gccacctacg
961 gcaagctgac cctgaagttc atctgcacca ccggcaagct gcccggtgcc tggccaccc
1021 tcgtgaccac cctgacctac ggcgtgcagt gcttcagccg ctaccccgac cacatgaagc

B, F & F Ref: CLON-069

Clontech Ref: P-90

F:\DOCUMENT\CLON\069\patent application.doc

5

10

15

20

25

30

35

40

45

50

55

1081	agcacgactt	cttcaagtc	gccatgccg	aaggtctagt	ccaggagcgc	accatcttct
1141	tcaaggacga	cggcaactac	aagaccgcg	ccgaggtgaa	gttcgagggc	gacaccctgg
1201	tgaaccgcat	cgagctgaag	ggcatcgact	tcaaggagga	cggcaacatc	ctggggcaca
1261	agctggagta	caactacaac	agccacaacg	tctatatcat	ggccgacaag	cagaagaacg
1321	gcatcaaggt	gaacttcaag	atccgccaca	acatcgagga	cggcagcgtg	cagctcgccg
1381	accactacca	gcagaacacc	cccacgcg	acggcccg	gctgctgccc	gacaaccact
1441	acctgagcac	ccagtccg	ctgagcaaag	accccaacga	gaagcgcgat	cacatggtcc
1501	tgctggagtt	cgtgaccg	gccgggatca	ctctcggc	ggacgagctg	tacaagtaaa
1561	gcggccgcga	ctctagatca	taatcagcca	taccacattt	gtagagggtt	tacttgcttt
1621	aaaaaacctc	ccacacctcc	ccctgaacct	gaaacataaa	atgaatgcaa	ttgttgttg
1681	taacttgttt	attgcagctt	ataatggtta	caaataaagc	aatagcatca	caaatttcac
1741	aaataaaagca	tttttttcac	tgcattctag	ttgttggttt	tccaaactca	tcaattgtatc
1801	ttaaaggcgta	aattgttaagc	gttaatat	tgttaaaatt	cgcgttaaat	tttgttaaa
1861	tcagctcatt	ttttaaccaa	taggcgaaa	tcggcaaaat	ccctataaa	tcaaagaat
1921	agaccgagat	aggggttgagt	gttgttccag	tttggaacaa	gagtccacta	ttaaagaacg
1981	tggactccaa	cgtcaaaggg	cgaaaaaccg	tctatcaggg	cgatggccca	ctacgtgaac
2041	catcacccta	atcaagtttt	ttggggtcga	ggtgcgtaa	agcactaaat	cggaaacct
2101	aaggagccc	ccgatttaga	gcttgacggg	gaaagccggc	gaacgtggcg	agaaaggaag
2161	ggaagaaagc	gaaaggagcg	ggcgctaggg	cgctggcaag	tgtagcggtc	acgctgcgcg
2221	taaccaccac	accgcgcgcg	cttaatgcgc	cgctacaggg	cgcgtcaggt	ggcacttttc
2281	gggaaatgt	gcgcggaacc	cctatttggt	tatttttcta	aatacattca	aatatgtatc
2341	cgctcatgag	acaataaccc	tgataaatgc	ttcaataata	ttgaaaaagg	aagagtcctg
2401	aggcgaaaag	aaccagctgt	ggaatgtgtg	tcagttaggg	tgtggaaagt	cccaggctc
2461	cccagcaggc	agaagtatgc	aaagcatgca	tctcaattag	tcagcaacca	ggtgtgga
2521	gtccccaggc	tccccagcag	gcagaagtat	gcaaagcatg	catctcaatt	agtcagcaac
2581	catagtcgg	cccctaactc	cgcctactcc	gcccctaact	ccgcccagtt	ccgcccattc
2641	tcgccccat	ggctgactaa	ttttttttat	ttatgcagag	gccaggccgc	cctcggccctc
2701	tgagctattc	cagaagtagt	gaggaggctt	ttttggaggc	ctaggctttt	gcaaagatcg
2761	atcaagagac	aggatgagga	tcgtttcgca	tgattgaaca	agatggattg	cacgcaggtt
2821	ctccggccgc	ttgggtggag	aggctattcg	gctatgactg	ggcacaacag	acaatcggt
2881	gctctgatgc	cgcctgtgtc	cggtgttcag	cgcaggggcg	ccgggttctt	tttgtcaaga
2941	ccgacctgtc	cggtgccctg	aatgaactgc	aagacgaggc	agcgcggcta	tcgtggctgg
3001	ccacgacggg	cgttccttgc	gcagctgtgc	tcgacgttgt	cactgaagcg	ggaagggact
3061	ggctgctatt	gggcgaagtg	ccggggcagg	atctcctgtc	atctcacctt	gctcctgcgc
3121	agaaagtatc	catcatggct	gatgcaatgc	ggcggtgca	tacgcttgat	ccggctacct
3181	gccatttcga	ccaccaagcg	aaacatcgca	tcgagcgagc	acgtactcgg	atggaagccg
3241	gtcttgtcga	tcaggatgat	ctggacgaag	agcatcaggg	gctcgcgcca	gccgaactgt
3301	tcgccaggct	caaggcgagc	atgcccgacg	gcgaggatct	cgtcgtgacc	catggcgatg
3361	cctgcttgcc	gaatatcatc	gtggaaaaatg	gcgcgttttc	tggatttcac	gactgtggcc
3421	ggctgggtgt	ggcggaccgc	tatcaggaca	tagcgttggc	taccctgat	attgctgaag
3481	agcttggcgg	cgaaatgggt	gaccgcttcc	tcgtgcttta	cggtatcgcc	gctcccgatt
3541	cgcagcgcat	cgccttctat	cgccttcttg	acgatttctt	ctgagcggga	ctctggggtt
3601	cgaaatgacc	gaccaagcga	cgcaccaact	gccatcacga	gatttcgatt	ccaccgcgc
3661	cttctatgaa	aggttgggct	tcggaatcgt	tttcggggac	gccggctgga	tgatcctcca
3721	gcgcggggat	ctcatgctgg	agttcttcgc	ccaccctagg	gggaggctaa	ctgaaacacg
3781	gaaggagaca	ataccggaag	gaaccgcgc	tatgacggca	ataaaaagac	agaataaaac
3841	gcacggtgtt	gggtcgtttg	ttcataaacg	cggggttcgg	tcccagggtc	ggcactctgt
3901	cgatacccca	ccgagacccc	attggggcca	atacgcgcgc	gtttcttcct	tttccccacc
3961	ccacccccca	agttcgggtg	aaggcccagg	gctcgcagcc	aacgtcgggg	cggcaggccc
4021	tgccatagcc	tcaggttact	catatatact	ttagattgat	ttaaaacttc	atttttaatt
4081	taaaaggatc	taggtgaaga	tccttttttg	taatctcatg	acaaaaatcc	cttaacgtga
4141	gttttcgttc	cactgagcgt	cgaccccgt	agaaaagatc	aaaggatctt	cttgagatcc
4201	ttttttctg	cgcgtaactc	gctgcttgca	aacaaaaaaa	ccaccgctac	cagcggtggt
4261	ttgtttgccg	gatcaagagc	taccaactct	ttttccgaag	gtaactggct	tcagcagact
4321	gcagatacca	aatactgtcc	ttctagtgt	gccgtagtta	ggccaccact	tcaagaactc
4381	tgtagcaccg	cctacatacc	tcgctctgct	aatcctgtta	ccagtggctg	ctgccagtgc

4441 cgataagtcg tgtcttaacg ggttggactc aagacgatag ttaccggata aggcgcagcg
 4501 gtcgggctga acggggggtt cgtgcacaca gccagcttg gagegaacga cctacaccga
 4561 actgagatac ctacagcgtg agctatgaga aagcgccacg cttcccgaag ggagaaaggc
 4621 ggacaggtat ccggttaagcg gcagggtcgg aacaggagag cgcacgaggg agcttccagg
 4681 gggaaacgcc tggatatctt atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg
 4741 atttttgtga tgctcgtcag gggggcggag cctatggaaa aacgccagca acgcggcctt
 4801 tttacggttc ctggcctttt gctggccttt tgctcacatg ttctttcctg cgttatcccc
 4861 tgattctgtg gataaccgta ttaccgcat gcat (SEQ ID NO:02)

10 C. pDNR-Dual-Luc

1 gcggccgcat aacttctgtat agcatacatt atacgaagtt atcagtcgac accatggaag
 61 acgcaaaaaa cataaagaaa ggcccggcgc cttctatcc tctagaggat ggaaccgctg
 121 gagagcaact gcataaggct atgaagagat acgccctggt tcttgaaca attgctttta
 181 cagatgcaca tatcgagggtg aacatcacgt acgcggaata cttcgaaatg tccgttcggt
 241 tggcagaagc tatgaaacga tatgggctga atacaaatca cagaatcgtc gtatgcagtg
 301 aaaactctct tcaattcttt atgccgggtg tgggcgcggt atttatcgga gttgcagttg
 361 cgcccgcgaa cgacatttat aatgaacgtg aattgctcaa cagtatgaac atttcgcagc
 421 ctaccgtagt gtttgtttcc aaaaaggggt tgcaaaaaat tttgaacgtg caaaaaaat
 481 taccaataat tcagaaaatt attatcatgg attctaaaac ggattaccag ggatttcagt
 541 cgatgtacac gttcgtcaca tctcatctac ctcccgggtt taatgagtac gattttgtac
 601 cagagtcctt tgatcgtgac aaaacaattg cactgataat gaattcctct ggatctactg
 661 ggttacctaa ggggtgtggc cttccgcata gaactgcctg cgtcagattc tcgcatgcc
 721 gagatcctat ttttggcaat caaatcattc cggatactgc gattttaagt gttgttccat
 781 tccatcacgg ttttggaaatg tttactacac tcggatattt gatatgtgga tttcgagtcg
 841 tcttaatgta tagatttgaa gaagagctgt ttttacgatc ctttcaggat tacaaaattc
 901 aaagtgcgtt gctagtacca accctatttt cattcttcgc caaaagcact ctgatgaca
 961 aatacgattt atctaattta cacgaatttg cttctggggg cgcacctctt tcgaaagaag
 1021 tcgggggaagc ggttgcaaaa cgcttccatc ttccagggat acgacaagga tatgggctca
 1081 ctgagactac atcagctatt ctgattacac ccgaggggga tgataaacgg ggcgcggtcg
 1141 gtaaaagtgt tccatttttt gaagcgaagg ttgtggatct ggataccggg aaaacgctgg
 1201 gcgttaatca gagaggcgaa ttatgtgtca gaggacctat gattatgtcc ggttatgtaa
 1261 acaatccgga agcgaccaac gccttgattg acaaggatgg atggctacat tctggagaca
 1321 tagcttactg ggacgaagac gaacacttct tcatagttga ccgcttgaag tctttaatta
 1381 aatacaaagg atatcaggtg gccccgctg aattggaatc gatattgtta caacacccca
 1441 acatcttcga cgcgggcgtg gcagggtctc ccgacgatga cgcgggtgaa cttccgcgcg
 1501 ccgttggtgt tttggagcac ggaaagacga tgacggaaaa agagatcgtg gattacgtcg
 1561 ccagtcaagt aacaaccgcg aaaaagttgc gcggaggagt tgtgtttgtg gacgaagtac
 1621 cgaaaaggtc tacccgaaaa ctgcagcga gaaaaatcag agagatcctc ataaaggcca
 1681 agaagggcgg aaagtccaaa ttgaggatcc gggcccagggt gagtggcatc aatcataatc
 1741 ataatacata tcataatcac aactagccta ggagatcctg gtcatagacta gtgcttggt
 1801 tctcaccaat aaaaaacgcc cggcggcaac cgagcgttct gaacaaatcc agatggagtt
 1861 ctgaggtcat tactggatct atcaacagga gtccaagcga gctcgatata aaattacgcc
 1921 ccgcctgccc actcatcgca gtactgttgt aattcattaa gcattctgcc gacatggaag
 1981 ccatacaaaa cggcatgatg aacctgaatc gccagcggca tcagcacctt gtcgccttgc
 2041 gtataatatt tgcccatggt gaaaacgggg gcgaagaagt tgtccatatt ggccacgttt
 2101 aaatcaaaac tggtgaaact caccaggga ttggctgaga cgaaaaacat attctcaata
 2161 aacccttttag ggaaataggg caggttttca ccgtaacacg ccacatcttg cgaatatatg
 2221 tgtagaaact gccggaaatc gtcgtggtat tcaactccaga gcgatgaaaa cgtttcagtt
 2281 tgctcatgga aaacggtgta acaagggtga aactatccc atatcaccag ctcaccgtct
 2341 ttcattgcca tacgaaattc cggatgagca ttcatacagg gggcaagaat gtgaataaag
 2401 gccggataaa acttgtgctt atttttcttt acggtcttta aaaaggccgt aatatccagc
 2461 tgaacggtct ggttataggt acattgagca actgactgaa atgcctcaaa atgttcttta
 2521 cgatgccatt gggatatatc aacggtggta tatccagtga tttttttctc catttttagct
 2581 tccttagctc ctgaaagatc cataacttcg tatagcatac attatacga gttatgcggc

B, F & F Ref: CLON-069

Clontech Ref: P-90

F:\DOCUMENT\CLON\069\patent application.doc

5

10

15

20

25

30

35

40

45

50

55

```

2641 cgcgacgtcc acatatacct gccgttccact attatttagt gaaatgagat attatgatat
2701 tttctgaatt gtgattaaaa aggcaacttt atgcccatgc aacagaaact ataaaaaata
2761 cagagaatga aaagaaacag atagattttt tagttcttta ggcccgtagt ctgcaaatcc
2821 ttttatgatt ttctatcaaa caaaagagga aaatagacca gttgcaatcc aaacgagagt
2881 ctaatagaat gaggtcgaaa agtaaactgc gccgggttgt tactgataaa gcaggcaaga
2941 cctaaaatgt gtaaagggca aagtgtatac tttggcgtca ccccttacat atttttaggtc
3001 tttttttatt gtgcgtaact aacttgccat cttcaaacag gagggctgga agaagcagac
3061 cgtaaacaca gtacataaaa aaggagacat gaacgatgaa catcaaaaag tttgcaaaac
3121 aagcaacagt attaaccttt actaccgcac tgctggcagg aggcgcaact caagcgtttg
3181 cgaaagaaac gaacccaaaag ccatataagg aaacatacgg catttcccat attacacgcc
3241 atgatatgct gcaaatccct gaacagcaaa aaaatgaaaa atatcaagtt cctgagttcg
3301 attcgtccac aattaaaaat atctcttctg caaaaggcct ggacgtttgg gacagctggc
3361 cattacaaaa cgctgacggc actgtcgcaa actatcacgg ctaccacatc gtctttgcat
3421 tagccggaga tcctaaaaat gccgatgaca catcgattta catgttctat caaaaagtcg
3481 gcgaaacttc tattgacagc tggaaaaacg ctggccgcgt ctttaaagac agcgacaaat
3541 tcgatgcaaa tgattctatc ctaaaagacc aaacacaaga atggtcaggt tcagccacat
3601 ttacatctga cggaaaaatc cgtttattct acactgattt ctccggtaaa cattacggca
3661 aacaaacact ggcaactgca caagttaacg tatcagcatc agacagctct ttgaacatca
3721 acggtgtaga ggattataaa tcaatctttg acggtgacgg aaaaacgtat caaaatgtac
3781 agcagttcat cgatgaaggc aactacagct caggcgacaa ccatacgtct agagatcctc
3841 actacgtaga agataaaggc cacaataact tagtatttga agcaaacact ggaactgaag
3901 atggctacca aggcgaagaa tctttattta acaaagcata ctatggcaaa agcacatcat
3961 tcttccgtca agaaagtcaa aaacttctgc aaagcgataa aaaacgcacg gctgagttag
4021 caaacggcgc tctcggtagt attgagctaa acgatgatta cactactgaa aaagtgatga
4081 aaccgctgat tgcattcaac acagtaacag atgaaattga acgcgcgaac gtctttaaaa
4141 tgaacggcaa atggtacctg ttcactgact cccgcggatc aaaaatgacg attgacggca
4201 ttacgtctaa cgataatttac atgcttggtt atgtttctaa ttctttaact ggcccataca
4261 agccgctgaa caaaactggc cttgtgttaa aaatggatct tgatcctaac gatgtaacct
4321 ttacttactc acacttctgt gtacctcaag cgaaaggaaa caatgtcgtg attacaagct
4381 atatgacaaa cagaggattc tacgcagaca aacaatcaac gtttgccctc agcttctctg
4441 tgaacatcaa aggcaagaaa acatctgttg tcaaagacag catccttgaa caaggacaat
4501 taacagttaa caaataaaaa cgcaaaagaa aatgccgata tcctattggc attgacgtca
4561 ggtggcactt ttcggggaaa tgtgcgcgga acccctattt gtttattttt ctaaatacat
4621 tcaaatatgt atccgctcat gagacaataa ccttgataaa tgcttcaata atattgaaaa
4681 aggaagagta tgagtattca acatttccgt gtccgccctta ttcccttttt tgcggcattt
4741 tgccttctctg tttttgctca ccagaaaacg ctggtgaaag taaaagatgc tgaagatcag
4801 ttgggtgcac gagtgggtta catcgaactg gatctcaaca gcggtgaagat ccttgagagt
4861 tttcgccccg aagaacgttt tccaatgatg agcactttta aagttctgct atgtggcgcg
4921 gtattatccc gtattgacgc cgggcaagag caactcggtc gccgcataca ctattctcag
4981 aatgacttgg ttgagtactc accagtcaca gaaaagcatc ttacggatgg catgacagta
5041 agagaattat gcagtgtctg cataaccatg agtgataaca ctgcggccaa cttacttctg
5101 acaacgatcg gaggaccgaa ggagctaacc gcttttttgc acaacatggg ggatcatgta
5161 actcgccttg atcgttgagg accggagctg aatgaagcca taccaaacga cgagcgtgac
5221 accacgatgc ctgtagcaat ggcaacaacg ttgcgcaaac tattaactgg cgaactactt
5281 actctagctt cccggcaaca attaatagac tggatggagg cggataaagt tgcaggacca
5341 cttctgcgct cggcccttcc ggctggctgg tttattgctg ataaatctgg agccggtgag
5401 cgtgggtctc gcggtatcat tgcagcactg gggccagatg gtaagccctc ccgtatcgta
5461 gttatctaca cgacggggag tcaggcaact atggatgaac gaaatagaca gatcgtgag
5521 ataggtgcct cactgattaa gcattggtaa ctgtcagacc aagtttactc atatatactt
5581 tagattgatt taaaacttca tttttaattt aaaaggatct aggtgaagat cctttttgat
5641 aatctcatga ccaaatccc ttaacgtgag ttttcgttcc actgagcgtc agaccccgta
5701 gaaaagatca aaggatcttc ttgagatcct tttttctgc gcgtaatctg ctgcttgcaa
5761 acaaaaaaac cacgcgtacc agcgttggtt tgtttgcgg atcaagactc accaactctt
5821 tttccgaagg taactggctt cagcagagcg cagataccaa atactgttct tctagtgtag
5881 ccgtagttag gccaccactt caagaactct gtagcaccgc ctacatacct cgctctgcta
5941 atcctgttac cagtggctgc tgccagtggc gataagtcgt gtcttaccgg gttggactca

```

B, F & F Ref: CLON-069

Clontech Ref: P-90

F:\DOCUMENT\CLON\069\patent application.doc

5

```

6001 agacgatagt taccggataa ggcgcagcgg tcgggctgaa cgggggggttc gtgcacacag
6061 cccagcttgg agcgaacgac ctacaccgaa ctgagatacc tacagcgtga gctatgagaa
6121 agcgccacgc ttcccgaagg gagaaaggcg gacaggtatc cggtaagcgg cagggtcgga
6181 acaggagagc gcacgaggga gcttccaggg ggaaacgcct ggtatcttta tagtcctgtc
6241 ggggttcgcc acctctgact tgagcgtcga tttttgtgat gctcgtcagg ggggcggagc
6301 ctatggaaaa acgccagcaa cgcggccttt ttacggttcc tggccttttg ctggcctttt
6361 gctcacatgt tctttcctgc gttatccctt gattctgtgg ataaccgtat taccgcctta
6421 cgcgtgtaaa acgacggcca gtagatctgt aatacgactc actatagggc gctagctgct
6481 cgccgcagcc gaacgaccga gcgcagcgag tcagtgcgag aggaa (SEQ ID NO:03)

```

10

D: pLPS-Luc-EGFP

15

20

25

30

35

40

45

50

```

1 tagttattaa tagtaatcaa ttacgggggtc attagttcat agcccatata tggagttccg
61 cgttacataa cttacggtaa atggcccgcg tggtcgaccg cccaacgacc cccgcccatt
121 gacgtcaata atgacgtatg ttcccatagt aacgcccaata gggactttcc attgacgtca
181 atgggtggag tatttacggg aaactgcccc cttggcagta catcaagtgt atcatatgcc
241 aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgccagta
301 catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac
361 catggtgatg cgggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg
421 atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg
481 ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggag gtaggcgtgt
541 acggtgggag gtctatataa gcagagctgg tttagtgaac cgtcagatcc gctagcataa
601 cttcgtatag catacattat acgaagttat cagtcgacac catggaagac gccaaaaaca
661 taaagaaagg cccggcgcca ttctatcctc tagaggatgg aaccgctgga gagcaactgc
721 ataaggctat gaagagatac gccctgggtc ctggaacaat tgcttttaca gatgcacata
781 tcgaggtgaa catcacgtac gcggaatact tcgaaatgtc cgttcggttg gcagaagcta
841 tgaacgata tgggctgaat acaaatcaca gaatcgtcgt atgcagttaa aactctcttc
901 aattctttat gccggtgttg ggcgcgttat ttatcggagt tgcagttgag cccgcgaacg
961 acatttataa tgaacgtgaa ttgctcaaca gtatgaacat ttgcgagcct accgtagtgt
1021 ttgtttccaa aaaggggttg caaaaaattt tgaacgtgca aaaaaatta ccaataattc
1081 agaaaattat tatcatggat tctaaaacgg attaccaggg atttcagtcg atgtacacgt
1141 tcgtcacatc tcatctacct cccggtttta atgagtacga ttttgtacca gagtcctttg
1201 atcgtgacaa aacaattgca ctgataatga attcctctgg atctactggg ttacctaaag
1261 gtgtggccct tccgcataga actgacctgc tcagattctc gcatgccaga gatcctatct
1321 ttggcaatca aatcattccg gatactgcga ttttaagtgt tgttccattc catcacgggt
1381 ttggaatggt tactactacc ggatatttga tatgtggatt tcgagtcgtc ttaatgtata
1441 gatttgaaga agagctgttt ttacgatccc ttcaggatta caaaattcaa agtgcgttgc
1501 tagtaccac cctatttttca ttcttcgcca aaagcactct gattgacaaa tacgatttat
1561 ctaattttaca cgaaattgct tctgggggag cacctctttc gaaagaagtc ggggaagcgg
1621 ttgcaaaacg cttccatctt ccagggatac gacaaggata tgggctcact gagactacat
1681 cagctattct gattacaccc gagggggatg ataaaccggg cgcggtcggg aaagttgttc
1741 cattttttga agcgaagggt gtggatctgg ataccgggaa aacgctgggc gttaatcaga
1801 gaggcgaatt atgtgtcaga ggacctatga ttatgtccgg ttatgtaaac aatccggaag
1861 cgaccaacgc cttgattgac aaggatggat ggctacattc tggagacata gcttactggg
1921 acgaagacga acacttcttc atagttgacc gcttgaagtc ttttaattaaa tacaaaggat
1981 atcagggtgg ccccgtgaa ttggaatcga tattgttaca acacccaac atcttcgacg
2041 cgggcgtggc aggtcttccc gacgatgacg ccggtgaact tcccgcggcc gttgttgttt
2101 tggagcacgg aaagacgatg acggaaaaag agatcgtgga ttacgtcgcc agtcaagtaa
2161 caaccgcgaa aaagttgcgc ggaggagttg tgtttgtgga cgaagtaccg aaaggtctta
2221 ccggaaaact cgacgcaaga aaaatcagag agatcctcat aaaggccaag aagggcggaa
2281 agtccaaatt gaggatccgg gcccagggtg gtggtcataa tcataatcat aatcataatc
2341 ataatcacia ctagcctagg agatcctggt catgactagt gcttggattc tcaccaataa
2401 aaaacgccc gcggcaaccg agcgttctga acaaatccag atggagttct gaggtcatta
2461 ctggatctat caacaggagt ccaagcgagc tcgatatcaa attacgcccc gccctgccac
2521 tcatcgcagt actgttgtaa ttcattaagc attctgccga catggaagcc atcacaacg

```

B, F & F Ref: CLON-069

Clontech Ref: P-90

F:\DOCUMENT\CLON\069\patent application.doc

5

10

15

20

25

30

35

40

45

50

55

```

2581 gcatgatgaa cctgaatcgc cagcggcacc agcaccttgt cgccttgcgt ataatatattg
2641 cccatggtga aaacgggggc gaagaagttg tccatatattg ccacgtttaa atcaaaactg
2701 gtgaaactca cccaggggatt ggctgagacg aaaaacatat tctcaataaa cccttttaggg
2761 aaataggcca ggttttcacc gtaacacgcc acatcttgcg aatatatgtg tagaaactgc
2821 cggaaatcgt cgtgggtattc actccagagc gatgaaaacg tttcagtttg ctcatggaaa
2881 acggtgtaac aaggggtgaac actatcccat atcaccagct caccgtcttt cattgccata
2941 cgaaattccg gatgagcatt catcaggcgg gcaagaatgt gaataaaggc cggataaaac
3001 ttgtgcttat ttttctttac ggtcttttaa aaggccgtaa tatccagctg aacggtctgg
3061 ttataggtac attgagcaac tgactgaaat gcctcaaaat gttctttacg atgccattgg
3121 gatatatcaa cgggtggtata tccagtgatt tttttctcca ttttagcttc cttagctcct
3181 gaaagatcca taacttcgta tagcatacat tatacgaagt tatagatcca atattattga
3241 agcattttatc aggggttattg tctcatgagc ggatacatat ttgaatgtat ttagaaaaat
3301 aaacaaatag gggttccgcg cacatttccc cgaaaagtgc cacctgacgt ggatctcgag
3361 ctcaagcttc gaattcaggg tttccttgac aatatcatat ttatcctgtc cctttttttt
3421 ccacagctac cggtcgcgag caagggcgag gagctgttca ccgggggtgg gcccatcctg
3481 gtcgagctgg acggcgacgt aaacggccac aagttcagcg tgcggcgga gggcgagggc
3541 gatgccacct acggcaagct gacctgaag ttcactgtca ccaccggcaa gctgcccggtg
3601 ccttgcccca cctcgtgac caccctgacc tacggcgtgc agtgcttcag ccgtaccccc
3661 gaccacatga agcagcacga cttcttcaag tccgccatgc ccgaaggcta cgtccaggag
3721 cgcaccatct tcttcaagga cgacggcaac tacaagacc gcgcgaggt gaagtccgag
3781 ggcgacaccc tgggtgaacc catcgagctg aagggcacgc acttcaagga ggacggcaac
3841 atcctggggc acaagctgga gtacaactac aacagccaca acgtctatat catggccgac
3901 aagcagaaga acggcatcaa ggtgaacttc aagatccgcc acaacatcga ggacggcagc
3961 gtgcagctcg ccgaccacta ccagcagaac acccccatcg gcgacggccc cgtgctgctg
4021 cccgacaacc actacctgag caccagtcg gccctgagca aagaccccaa cgagaagcgc
4081 gatcacatgg tcctgctgga gttcgtgacc gccgcccggg tcaactctcg catggacgag
4141 ctgtacaagt aaagcggccg cgactctaga tcataatcag ccataccaca ttgttagagg
4201 ttttacttgc tttaaaaaac ctcccacacc tccccctgaa cctgaaacat aaaatgaatg
4261 caattgttgt tggttaactt tttattgcag cttataatgg ttacaaataa agcaatagca
4321 tcacaaatct cacaaataaa gcattttttt cactgcattc tagttgtggt ttgtccaaac
4381 tcatcaatgt atcttaaggc gtaaattgta agcgttaata ttttggttaa attcgcgtta
4441 aattttttgt aaatcagctc attttttaac caataggccg aaatcggaac aatcccttat
4501 aaatcaaaag aatagaccga gatagggttg agtggtgttc cagtttgtaa caagagtcca
4561 ctattaaaga acgtggactc caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc
4621 ccactacgtg aacctacacc ctaatcaagt tttttgggt cgaggtgccg taaagacta
4681 aatcggaacc ctaaaggag ccccgattt agagcttgac ggggaaagcc ggcgaacgtg
4741 gcgagaaagg aagggaagaa agcgaaagga gcggcgcta gggcgctggc aagtgtagcg
4801 gtcacgctgc gcgtaaccac cacaccgcc gcgcttaatg cgccgctaca gggcgctca
4861 ggtggcactt ttccgggaaa tgtgcgcgga acccctattt gtttattttt ctaatacat
4921 tcaaatatgt atccgctcat gagacaataa ccctgataaa tgcttcaata atattgaaaa
4981 aggaagagtc ctgaggcgga aagaaccagc tgtggaatgt gtgtcagtta ggggtgtgaa
5041 agtccccagg ctcccagca ggcagaagta tgcaaagcat gcatctcaat tagtcagcaa
5101 ccagggtgtg aaagtcccca ggctccccag caggcagaag tatgcaaagc atgcatctca
5161 attagtcagc aaccatagtc ccgccccta ctccgccc atccgccccta actccgccc
5221 gttccgccc ctctcgccc catggtgac taattttttt tatttatgca gaggccgagg
5281 ccgcctcggc ctctgagcta ttccagaagt agtgaggagg ctttttttga ggccataggc
5341 tttgcaaaga tcgatcaaga gacaggatga ggatcgtttc gcatgattga acaagatgga
5401 ttgcacgcag gttctccggc cgcttgggtg gagaggctat tcggctatga ctgggcacaa
5461 cagacaatcg gctgctctga tgccgcctg ttccggctgt cagcgcaggg gcgcccgggt
5521 ctttttgtca agaccgacct gtccggtgcc ctgaatgaac tgcaagacga ggcagcgcg
5581 ctatcgtggc tggccacgac gggcggtcct tgccgagctg tgcctgacgt tgtcactgaa
5641 gcgggaaggg actggctgct attggcgaa gtgcccgggc aggatctcct gtcactcac
5701 cttgctcctg ccgagaaagt atccatcatg gctgatgcaa tgcggcggtg gcatacgtct
5761 gatccggcta cctgcccatt cgaccaccaa gcgaaacatc gcacgcagcg agcacgtact
5821 cggatggaag ccggtcttgt cgatcaggat gatctggacg aagagcatca ggggctcgcg
5881 ccagccgaac tgttcgccag gctcaaggcg agcatgcccg acggcgagga tctcgtcgtg

```

B, F & F Ref. CLON-069

Clontech Ref. P-90

F:\DOCUMENT\CLON\069\patent application.doc

5941 acccatggcg atgcctgctt gccgaatata atggtggaaa atggccgctt ttctggattc
6001 atcgactgtg gccggctggg tgtggcggac cgctatcagg acatagcggt ggctacccgt
6061 gatattgctg aagagcttgg cggcgaatgg gctgaccgct tctctgtgct ttacgggtatc
6121 gccgctcccg attcgcagcg catcgcttcc tatcgcttcc ttgacgagtt cttctgagcg
6181 ggactctggg gttcgaaatg accgaccaag cgacgccccaa cctgccatca cgagatttcg
6241 attccaccgc cgccttctat gaaaggttgg gcttcggaat cgttttccgg gacgccggct
6301 ggatgatcct ccagcgcggg gatctcatgc tggagtctt cgcccaccct agggggaggc
6361 taactgaaac acggaaggag acaataaccg aaggaaccg cgctatgacg gcaataaaaa
6421 gacagaataa aacgcacggg gttgggtcgt ttgttcataa acgcgggggt cgggtcccagg
6481 gctggcactc tgtcgatacc ccaccgagac ccattgggg ccaatacgcc cgcgtttctt
6541 ccttttcccc accccacccc ccaagttcgg gtgaaggccc agggctcgca gccaacgtcg
6601 gggcggcagg ccctgccata gctcagggt actcatatat actttagatt gatttaaaac
6661 ttcatTTTTa atttaaaagg atctagggtga agatcctttt tgataatctc atgacaaaaa
6721 tcccttaacg tgagttttcg ttccactgag cgtcagacc cgtagaaaag atcaaaggat
6781 cttcttgaga tctttttttt ctgcgcgtaa tctgtgctt gcaaacaaaa aaaccaccgc
6841 taccagcggg ggtttgtttg ccggatcaag agctaccaac tcttttccg aaggttaactg
6901 gcttcagcag agcgcagata ccaaatactg tcttctagt gtagccgtag ttaggccacc
6961 acttcaagaa ctctgtagca ccgcctacat acctcgctct gctaattcctg ttaccagtgg
7021 ctgctgccag tggcgataag tctgtcttta ccgggttggg ctcaagacga tagttaccgg
7081 ataaggcgca gcggtcgggc tgaacggggg gttcgtgcac acagcccagc ttggagcgaa
7141 cgacctacac cgaactgaga tacctacagc gtgagctatg agaaagcgcc acgcttcccg
7201 aaggagagaaa ggcggacagg tatccggtta gccgcagggt cggaacagga gagcgcacga
7261 gggagcttcc agggggaaac gcctgggtatc tttatagtcc tgtcgggttt cgccacctct
7321 gacttgagcg tcgatttttg tgatgctcgt cagggggggc gagcctatgg aaaaacgcca
7381 gcaacgcggc ctttttacgg ttcttgccct tttgctggcc ttttgctcac atgttctttc
7441 ctgcgttatc ccctgattct gtggataacc gtattaccgc catgcat (SEQ ID NO:04)

Example 3. Representative Splice Donor and Acceptor Sites

30 A. Consensus Splice Donor and Acceptor oligos:

Consensus splice donor:
(cloned into pDNR-1 at Apal and AvrII sites)

35 Site of Exon/intron boundary |
top : CAGGTGAGTTAGGTAAGTGAACATGGTCATAGCTGTTTC
bottom: CCGGGTCCACTCAATCCATTCACTTGTACCAGTATCGACAAAGGATC
(SEQ ID NOS: 05 & 06)

40 Consensus splice acceptor (includes branch site): (cloned into pEGFP-N1 at EcoRI and AgeI sites)

Site of Exon/intron boundary |
top : AATTCAGGGTTTCCTTGACAATATCATACTTATCCTGTCCCTTTTTTTTCCACAGCTA
45 bottom: GTCCCAAAGGAACTGTTATAGTATGAATAGGACAGGGAAGGTGTTCGATGGCC

(SEQ ID NOS:07 & 08)

50 B. Splice donor from Human hemoglobin Beta

[illegible]

(SEQ ID NOS: 09 & 10)

20 Oligo for Splice Donor from Human Hemoglobin Intron I with added Stops and (HN)6 tag:

(SEQ ID NOS:11&12)

35 Top : GGT CAT AAT CAT AAT CAT AAT CAT AAT CAT AAT CAC AAC TAG
 Bottom: CCA GTA TTA GTA TTA GTA TTA GTA TTA GTA TTA GTG TTG ATC
 Peptide encoded: Gly His Asn His Asn His Asn His Asn His Asn His Asn stop

(SEQ ID NOS:13, 14 17 15)

45 This oligo encodes the splice Acceptor region of intron I from Human Hemoglobin Beta together with flanking exoon sequence. It was cloned into pEGFP-N1 at the AgeI and EcoR I sites.

B, F & F Ref: CLON-069
Clontech Ref: P-90
F:\DOCUMENT\CLON\069\patent application.doc

Top :
AATTCTTGGGTTTCTGATAGGCACTGACTCTCTCTGCCGATTGGTCTATTTTCCCACCCTTAGGCTGCTGGTGGTCTACC
CTTGGACCCTA

Bottom:

5 GAACCCAAAGACTATCCGTGACTGAGAGAGACGGCTAACCAGATAAAAGGGTGGGAATCCGACGACCACCAGATGGGAAC
CTGGGATGGCC

(SEQ ID NOS: 16 & 17)

It is evident from the above results and discussion that the subject
10 invention provides an efficient method to transfer a nucleic acid from a first vector
to a second vector, where the subject methods do not employ digestion and
ligation protocols. Advantages provided by the subject invention include: the
ability to transfer or clone a nucleic acid of interest from a single donor into a
variety of different expression vectors at substantially the same time and in a
15 known orientation and reading frame; the ability to readily identify successful
clones; the ability to transfer many different genes to one or more expression
vectors simultaneously; no longer needing to sequence the junctions of the
transferred fragment and the expression vector or to resequence the gene
transferred and the like. Another advantage of the subject invention is to provide
20 for introns in the product vector, so as to remove any unwanted sequences from
the final encoded product, and/or easily produce N- and/or C-terminal tagged
fusion proteins. As such, the subject invention represents a significant
contribution to the art.

25 All publications and patent applications cited in this specification are herein
incorporated by reference as if each individual publication or patent application
were specifically and individually indicated to be incorporated by reference. The
citation of any publication is for its disclosure prior to the filing date and should not
be construed as an admission that the present invention is not entitled to
30 antedate such publication by virtue of prior invention.

Although the foregoing invention has been described in some detail by way
of illustration and example for purposes of clarity of understanding, it is readily
apparent to those of ordinary skill in the art in light of the teachings of this

22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 10